HealthLeaders Media Launches Free Online Daily Business Newsletter for Physician Leaders - PhysicianLeaders Daily NewsPhysicianLeaders Daily News, a new free online publication offering daily updates on top business news of the day for physician leaders, is now available.
Marblehead, MA (PRWEB) January 31, 2006 -- PhysicianLeaders Daily News, a new free online publication offering daily updates on top business news of the day for physician leaders, is now available.
Physician leaders need timely, accurate and relevant business information every day. Physicians are trained to sift through myriad bits of information to come up with only what is essential. This same philosophy guides our editorsthe same team of journalists who bring you HealthLeaders magazine and HealthLeaders Daily News. We look for the national stories that have implications for physician leaders, as well as some of the local and regional issues that could impact their practice.
Todays physician leader is being bombarded with information at the same time that the business side of medicine increases in complexity, says HealthLeaders editor Jim Molpus. This newsletter is designed to be a streamlined way for physicians to stay current on the business of healthcare.
Every issue will feature a handful of links to the top news of the day from newspaper Web sites across the country. PhysicianLeaders Daily News also offers quick, action-oriented insight, from new ways to make the practice more efficient, to updates on policy from Washington. Peer insight comes from contributed columns from experts in the medicine. Plus, the PhysicianLeaders Daily News offers abstracts and exclusive bonus content from the physician practice expert newsletters of HCPro, Inc.
PhysicianLeaders Daily News is delivered to a physicians inbox every day for free, in an easy-to-read format. Readers may go to www.healthleadersmedia.com/subscribe to sign up.
To sponsor PhysicianLeaders Daily News contact Sara Law at 800.639.7477.
About HealthLeaders Media
HealthLeaders Media, a division of HCPro, Inc, is the premier publisher of information resources for senior executives at healthcare organizations. Each month, more than 100,000 healthcare executives and key decision makers nationwide turn to HealthLeaders Media for timely industry information and practical advice on trends and innovations, strategy, case-study solutions, and opinions. As an integrated media company, HealthLeaders Media consists of the monthly HealthLeaders magazine, several healthcare business e-mail publications, live events, and a state-specific healthcare business news service. Advertising vehicles include print ads, online sponsorships, banner ads, e-mails, Webcasts, roundtables and custom publishing products. For more information, visit them online at www.healthleadersmedia.com.
Contact:
Matt Cann, Group Publisher
Phone: 781-639-1872 ext. 3233
Mark H. Hollister, General Manager
Phone: 888.834.4678
# # #
Press Contact: Matt Cann
Company Name: HCPRO
Email: email protected from spam bots
Phone: 781-639-1872
Website: www.healthleadersmedia.com/subscribe
The National Council on the Aging (NCOA) and the Access to Benefits Coalition (ABC) have recently launched My Medicare Matters nationwide in an effort to provide much needed impartial educational support for seniors at local events and community centers via computer equipped vans and expertly trained educators. The program is supported by The Minnesota Senior Federation, the primary grassroots organization of seniors in Minnesota. With more than 20,000 members and 100 affiliated organizations, the Federation is dedicated to helping seniors develop leadership skills and work toward positive social change locally, statewide and throughout the nation.
The My Medicare Matters team of educators will meet with individuals, family members and/or caregivers for 10 minutes ... 45 minutes ... or more until each senior's questions and concerns have been addressed.
At the events, seniors can sit down with benefits educators who will provide private, personalized guidance as they learn about the new coverage and their options. The educators will use the latest technology via Web-enabled computers, and use Internet-based tools during counseling sessions to help seniors compare plans and make the enrollment decision that is right for their health and their financial situation.
If and when seniors are ready to join a plan, the My Medicare Matters (TM) educators will also assist them in completing the online enrollment process or advise them about other methods for joining a plan.
My Medicare Matters sessions will be held according to the following schedule. Sessions at each location are always held from 1:00 p.m. to 4:00 p.m.:
-- Thursday, Feb. 2, 2006, Cub Foods, 7555 W. Broadway Ave., Brooklyn Park;
-- Friday, Feb. 3, 2006, Cub Foods, 250 33rd Ave. So., St. Cloud;
-- Wednesday, Mar. 1, 2006, Cub Foods, 2859 26th Ave. So., Minneapolis;
-- Friday, Mar. 3, Cub Foods, 2001 So. Robert St., West St. Paul;
-- Tuesday, Mar. 14, Cub Foods, 15350 Cedar Ave.; Apple Valley;
-- Monday, Mar. 27, Cub Foods, 2197 Old Hudson Rd., St. Paul;
-- Thursday, Mar. 30, Cub Foods, 1440 University Ave., St. Paul;
-- Wednesday, Apr. 5, Cub Foods, 8690 E. Point Douglas Rd., Cottage Grove;
-- Wednesday, April 12, Cub Foods, 701 W. Broadway Ave., Minneapolis;
-- Friday, Apr. 21, Cub Foods, 5397 Nicollet Ave., Minneapolis;
-- Tuesday, Apr. 25, Cub Foods, 7435 179th St., Lakeville;
-- Tuesday, May 2, Cub Foods, 1729 Market Blvd., Hastings;
-- Wednesday, May 10, Cub Foods, 4801 Hwy. 101, Minnetonka;
-- Monday, May 15, Cub Foods, 1059 Meadowlands Dr., White Bear Lake.
The Web site, www.MyMedicareMatters.org, is available for use by Medicare participants, and their families, friends, caregivers, professionals and organizations. The Web site provides educational materials, and Internet tools that can be used to learn about Medicare Part D, and links them to CMS' Medicare Prescription Drug Plan Finder. People who visit www.MyMedicareMatters.org will also be able to enroll online or request extra help from the Social Security Administration.
Nationally, My Medicare Matters has deployed a fleet of 37 mobile education vans that are bringing trained staff and technology to 27 states and the District of Columbia to offer help in 44 metro areas and nearly 300 counties across the country. My Medicare Matters intends to hold informational events in the Twin Cities throughout the Medicare Part D enrollment period which ends on May 15, 2006.
My Medicare Matters is being supported by AstraZeneca Pharmaceuticals LP, fulfilling the company's mission to improve patient health for seniors across the country. "We believe the Medicare Prescription Drug Benefit can make a tremendous contribution to the quality of life for millions of Americans and we commend the NCOA and the ABC for offering this crucial educational program for seniors," said Tony Zook, President and CEO designate.
Additional My Medicare Matters sessions are being scheduled at Cub Pharmacies. Consumers interested in attending should call their local Cub Pharmacy for a schedule of events. Consumers also may contact the Senior Linkage Line at 1-800-333-2433.
Avian Flu Talk Launches New Discussion ForumAvian Flu Talk hosts forum for discussions relating to H5N1 bird flu virus.
(PRWEB) January 30, 2006 -- Avian Flu Talk recently announced that it had launched a discussion forum dedicated to discussing issues relating to the H5N1 bird flu virus. Over the last 90 days, this new forum has rapidly grown to be one of the most active forums in the world. The new forum appears to be capturing the publics attention as people continue to join this community in waves.
Perhaps the forum is appealing to so many around the world because of the overall caring nature being displayed among the members, said Ryan Evans, founder of the forum. The people on this forum also seem to be taking a united stance against the growing pandemic threat, which is also attracting people to the site.
The new website recently added new informative forums that are designed to help educate the public on pandemic preparedness. The addition of these new forums will provide a great service to the world, said Evans, who attributed these latest enhancements to the forum Moderator.
In addition, this forum is a great news source to receive all of the latest information and developments regarding the bird flu as its members share news articles from around the world.
View the forum at www.Avianflutalk.com .
Media Contact:
Ryan Evans
Avian Flu Talk
P.O. Box 1294
Stanton, California 90680
714.965.5950
www.Avianflutalk.com
# # #
Press Contact: Ryan Evans
Company Name: Avian Flu Talk
Email: email protected from spam bots
Phone: 714.965.5950
Website: www.Avianflutalk.com
"Our ongoing investment in Merchandising reflects our continued commitment to this industry," said Dale Christopherson, director, Retail Product Development, Lawson Software. "Based on the feedback provided by our retail customers, we're focusing our product development resources on Merchandising enhancements that will help save our customers time and help deliver a significantly lower total cost of ownership."
Lawson is updating seven applications within its Merchandising suite, including Category Review, Distribution, Retail Channel Order Management, Costs and Deals, Replenishment, Business Organizer and Reference Maintainer.
Lawson's industry-focused software solutions help retailers integrate the systems they use to run and grow their businesses. Lawson customers include five of the top 10 U.S.-based retailers, eight of the top 20 apparel retailers, seven of the top 25 grocery chains, 23 of the top 100 restaurant chains and 20 of the top 100 specialty chains.
About Lawson Software
Lawson Software provides business application software and consulting services to services organizations in the healthcare, retail, government and education, banking and insurance and other markets. Lawson's software suites include enterprise performance management, distribution, financials, human capital management, procurement, retail operations and service process optimization. With headquarters in St. Paul, Minn., Lawson has offices and affiliates serving North and South America, Europe, and Africa. Lawson Software and Lawson are registered trademarks of Lawson Software, Inc. All rights reserved.
Forward-Looking Statements
This press release contains forward-looking statements that contain risks and uncertainties. These forward-looking statements contain statements of intent, belief or current expectations of Lawson Software, Inc., and its management. Such forward-looking statements are not guarantees of future results and involve risks and uncertainties that may cause actual results to differ materially from the potential results discussed in the forward-looking statements. The company is not obligated to update forward-looking statements based on circumstances or events that occur in the future. Risks and uncertainties that may cause such differences include but are not limited to: uncertainties in the company's ability to realize synergies and revenue opportunities anticipated from the Intentia International acquisition; uncertainties in the software industry; global military conflicts; terrorist attacks in the United States, and any future events in response to these developments; changes in conditions in the company's targeted service industries; increased competition and other risk factors listed in the company's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission and as included in other documents the company files from time to time with the Commission.
| Lawson Software | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||
Federal Register Publishes TÜV Healthcare Specialists Application for Medicare Deeming AuthorityHealthcare quality firm TÜV Healthcare Specialists (TÜVHS) today announced that its application to the Centers for Medicare & Medicaid Services (CMS) for deeming authority has been published in the Federal Register.
Cincinnati, OH (PRWEB) January 30, 2006 -- Healthcare quality firm TÜV Healthcare Specialists (TÜVHS) today announced that its application to the Centers for Medicare & Medicaid Services (CMS) for deeming authority has been published in the Federal Register.
The CMS request for public comments in the Federal Register is a key administrative milestone in the months-long process to achieve CMS hospital deeming authority for Medicare. TÜVHS completed its formal application for deeming authority in December. Posting in the Federal Register (http://www.gpoaccess.gov) moves the process into the public domain as a way to inform and involve healthcare leaders and the general public.
January has been a significant month for us, says Rebecca Wise, CEO of TÜVHS. In addition to expanding our ISO 9001 and accreditation teams, we have been undergoing a rigorous evaluation of our operations by CMS. We want to be ready when CMS issues their decision.
If granted deeming authority, TÜVHS will become the first new option for CMS hospital accreditation in 40 years, and the only service to integrate the ISO 9001 Quality Management System into the accreditation process.
About TÜV Healthcare Specialists
TÜVHS (TÜV America Healthcare Specialists TÜV SUD Group LLC) is an experienced healthcare quality company dedicated to improving safety and patient outcomes in Americas hospitals. TÜVHS is a subsidiary of the international quality management and product testing company TÜV America. TÜV America is a Registrar for the international ISO 9001 Quality Management System. For more information visit: www.tuvhs.com.
# # #
Press Contact: Peter Greer
Company Name: TUV Healthcare Specialists
Email: email protected from spam bots
Phone: 978-462-8042
Website: www.tuvhs.com
MediComm Patient Flow System Integrates with Centricity Physician Office Practice Management SystemVisionary Systems announces new Reception Desk Software that integrates its MediComm exam room management system with Centricitys Patient scheduling module.
(PRWEB) January 30, 2006 -- Visionary Systems announces new Reception Desk Software that integrates its MediComm exam room management system with Centricitys Patient scheduling module.
Centricity, the industry's leading practice management software, can now forward patient information to Visionary System's MediComm exam room management system.
When the receptionist checks a patient in using Centricity, the patient's name and the name of their physician are automatically sent to the MediComm system. The MediComm system then keeps track of patients as they are assigned to exam rooms, taken to the x-ray suite, or to the lab for blood work. Throughout these movements within the office, the MediComm system maintains the proper priority of the patient relative to other patients.
Norma Morrison, vice president of operations at Foundry Sports Medicine and Fitness in Providence, Rhode Island says One of our concerns coming to our new office was the communication from the front desk to the patient treatment area. The MediComm system handles this without extra steps or wasted time in walking up front, and eliminates confusion if a medical assistant/x-ray tech is busy and does not hear an overhead page. The MediComm system is foolproof and has exceeded our expectations.
The heart of the MediComm system is an LCD touch screen mounted at the back nurse's desk. Along with a full floor plan of the exam room status, the MediComm system displays a list of patients in the waiting room. Using the touch screen, a staff member assigns patients an exam room, which alerts the doctor that the patient is ready. Modules outside each exam room display the name of the patient in the room, as well as which room the doctor should go to next. User defined pushbuttons on the modules allow the doctor to call for additional services such as an x-ray, medical assistant, or lab tech.
Morrison added We no longer use paper charts. But without the chart on the door, the doctors wouldn't have known the name of the patient in the exam room. The MediComm system not only lets the doctor know who is in the room, but also the order of rooms to visit - even if a patient left the exam room for an x-ray, and is now back and awaiting the results. Our staff always knows what to do and where to go next.
About VISIONARY SYSTEMS and MEDICOMM.
The MediComm is a sophisticated and user-friendly communication system. It allows doctors to request specific staff assistance, and directs doctors to their next patient. It is the ultimate exam room signaling system.
A central display panel gives an overview of the entire office, while modules at each exam room allow quick data entry and focused information display.
MediComm can streamline traffic and information flow in your office. MediComm:
Indicates which rooms are free.
Tells the doctor which room he has patients in and keeps them in order so he knows which room to go to next.
Allows the doctor to call a particular nurse or tech service with enough detail so that the assistant arrives prepared.
To learn more visit http://visionary-systems.com or call 401-643-1765.
# # #
Press Contact: Marshall Huggins
Company Name: Visionary Systems
Email: email protected from spam bots
Phone: 401-643-1765
Website: http://visionary-systems.com
Genta Incorporated has entered the first patient into a new clinical study that will evaluate the bioactivity and safety of the company's lead anticancer drug, Genasense Injection, administered by intermittent subcutaneous injection. The study employs a new formulation of Genasense that is five-fold more concentrated than material currently used in clinical trials. Having completed requisite animal toxicology work, the trial is proceeding pursuant to a separate investigational new drug application that was filed with the FDA. Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced cell death. By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. A prolonged subcutaneous infusion method using the existing intravenous formulation of the drug has been studied in patients with advanced non-Hodgkin's lymphoma. In this study the drug showed anti-tumor activity as a single agent and documented down-regulation of Bcl-2. The new program seeks to extend these initial observations in a formal dose-ranging trial using the new, highly concentrated formulation. "Genasense has demonstrated synergy with various treatments, such as Tarceva, interferon and radiation, all of which require multi-day schedules," commented Dr Raymond Warrell, Genta's chairman and CEO. "The new method may substantially increase patient convenience and expand the utility of Genasense, particularly in front-line and adjuvant settings."
PMI Announces the 2006 National Conference for Certified Professionals to be held in San Antonio, TexasPractice Management Institute (PMI), a leading provider of medical office continuing education, today announced its National Conference for Certified Professionals, to be held on May 18 & 19, 2006 on the River Walk in San Antonio.
San Antonio, TX (PRWEB) January 27, 2006 -- Practice Management Institute (PMI), a leading provider of medical office continuing education, today announced its National Conference for Certified Professionals, to be held on May 18 & 19, 2006 on the River Walk in San Antonio.
This conference is jam-packed with information critical to the physicians office. Topics such as: EMRs -- Should you Implement a Paperless System?, Pay For Performance and Consumer Driven Healthcare and Making Sense of the New Competitive Acquisition Plan will be profiled at this years conference, said Lynn Ballard, Conference Chair and VP of Professional Services for Practice Management Institute. These sessions will be presented along with 20 other classes highlighting critical administrative issues that impact todays physicians and their practices.
PMIs veteran faculty team will present the program, along with guest presenters, including Stan Luke, Deputy Chief, U.S. District Attorneys Office, Civil Division, Department of Justice, and Michael Brown, Contributing Editor for Medical Economics. Round table discussions, customized breakout sessions and networking luncheons are planned to promote group interaction with conference participants and faculty members.
Participants are encouraged to register early, as the conference will be capped at 300 participants. This year, PMI celebrates 25 years of coding, reimbursement and practice management training. The federal government recently recognized PMIs Certified Medical Coder (CMC) program. In 2004, the Centers for Medicare and Medicaid Services (CMS) named PMIs Certified Medical Coder program as an example coder certification programs that could be utilized to fulfill its coding certification requirement of Medicare Contractors. The requirement stems from implementation guidelines for the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (MMA). This recognition reinforces PMIs position as a top provider of certification for medical office staff.
PMI training and certification classes are currently presented to physicians and their staffs in 400 of the nations leading hospitals, health care systems, colleges and medical societies. For more information, visit www.pmiMD.com or call 800-259-5562.
###
Press Contact: Nancy Clements
Company Name: PRACTICE MANAGEMENT INSTITUTE
Email: email protected from spam bots
Phone: 210-691-8900
Website: www.pmimd.com
MD-IT Adds Operations ExecutiveMD-IT, an industry leader in integrating automated tools with medical transcription to assist physicians in documentation of medical care, announced today that Michael Murphy has joined the Company as Vice President of Operations.
Denver, CO (PRWEB) January 27, 2006 -- MD-IT, an industry leader in integrating automated tools with medical transcription to assist physicians in documentation of medical care, announced today that Michael Murphy has joined the Company as Vice President of Operations.
Mr. Murphy brings twenty-five years of leadership and management experience with both start-up and Fortune 500 firms in software and services businesses. He has distinguished himself as an effective leader with a strong customer service orientation. After beginning his career at Verac, Inc. and later Ball Corporation, Mr. Murphy co-founded Colorado-based Requisite Technology and has been a key member of several successful Colorado startup companies. Most recently, Mr. Murphy served as the Vice President and COO of CTEK, a Colorado-based organization that helps entrepreneurs launch and develop new growth businesses.
Ive had my eye on MD-IT for the past couple of years, said Murphy, and Im impressed by the cutting-edge technology it has developed and is now deploying to deliver state-of-the-art medical transcription services. Im excited to be joining the company at this juncture, as it accelerates its growth to apply its medical transcription solutions more widely.
The addition of Mr. Murphy is an important commitment to ensure timely, world-class customer support and service. MD-ITs goal is to make it easy for physicians to use twenty-first century technology in their medical practices without complicating their workload or distracting from physician-patient interactions. Physicians have enough time demands just keeping up with medical advances in their specialty area, much less having time to research and apply the latest advances in information technology, noted Thomas Carson, president and CEO of MD-IT. Our business is to integrate new technology seamlessly into the medical transcription process, so that when an individual physician is ready to try a new tool, such as automated voice recognition, we can switch on that function as part of their existing transcription service. The best part is that the more technology is used, the less expensive documentation becomes, so we can actually help a medical practice decrease operating costs over time while creating an electronic record.
About MD-IT
MD-IT provides Intelligent Transcription services and products to over 300 physicians in 90 clinics and group practices. Intelligent Transcription uses new technology to transform old services by providing a full range of automated tools that enable fast and easy document creation and exchange among physician offices, medical transcriptionists and information systems, while retaining personalized service to support individual physician preferences. Located in Denver, Colorado, the company is financed by equity investments from strategic partners and private investors. Additional information can be found at www.md-it.com.
Intelligent Transcription - New Technology Transforming Old Services
Media Contact
Thomas Carson President and CEO, 720-932-6262 x411
# # #
Press Contact: Thomas Carson
Company Name: MD-IT
Email: email protected from spam bots
Phone: 720-932-6262
Website: www.md-it.com
| Environmental Controls for Sterile Compounding Technical Paper A guidance document on developing sterile preparation areas to meet the USP <797> requirements for low and medium risk compounded sterile Preparations (CSPs). | |
| ABSTRACT This paper provides clarification and possible alternatives for designing room layouts, engineering controls, and equipment that provide the necessary level of environmental control to satisfy the requirements for compounding sterile preparations in compliance with USP 797. The standard is presented in sections that include: compounding personnel responsibilities, risk level classifications, verification of compounding accuracy/sterility, quality assurance and quality control, event and patient monitoring, training and evaluation, and environmental quality and control. This paper addresses environmental quality and control issues. INTRODUCTION USP Chapter <797>, released in January 2004, created a new (US) national standard for sterile preparation. The standard resulted from the efforts of earlier organizations to improve the quality and consistency of sterile preparations. These groups included the National Coordinating Commitee on Large Volume Parenterals (NCCLVP), the American Society for Health-System Pharmacists (ASHP) Guidelines, USP Chapter <1206>, FDA Modernization Act of 1997 (FDAMA) and the National Association of Boards of Pharmacy (NABP). The new standard is intended to describe the current best practice for quality assurance in compounding in an effort to improve patient safety and reduce the number of adverse events related to compounding activities. There is still debate within the pharmacy profession about what the requirements are to fully comply with this new standard. However, what individuals can agree on is that the practices of the past are going to change, particularly in hospitals. The extent of change necessary to achieve 兎xcellent・results will be determined over time as the Chapter guidelines are interpreted and individual (facility) responses are audited for compliance. Refer to the USP Web site (www.usp.org) and the JCAHO Perspectives newsletter (www.jcaho.org) for current guidance on the regulations. UNDERSTANDING CLEANROOMS The International Standards Organization (ISO) defines a cleanroom as, 鄭 room in which the concentration of airborne particles is controlled, and which is constructed and used in a manner to minimize the introduction, generation, and retention of particulates inside the room, and in which other relevant parameters, e.g., temperature, humidity, pressure, are controlled as necessary.・ Control in this context means that a selected parameter is governed by procedure and practice, is routinely measured, and prescribed action is taken if that parameter exceeds predetermined limits. ISO 14644 classifies nine levels of cleanroom based upon particle counts within one cubic meter of room air. ISO Class 1 is the highest or cleanest rating, with Class 9 being the lowest. A number of third-party vendor offer particle counting services. There are also cleanroom particle counters available for sale that can be used to evaluate the cleanliness of sterile compounding preparation areas. The Cleanrooms (http://cr.pennnet.com /home.cfm) and Cleanroom Technology (http://www.cleanroom-technology.co.uk/) magazine Web sites both offer references and resources for determining current state of environmental control, as well as information on designing and constructing cleanrooms, and purchasing cleanroom equipment. REQUIREMENTS USP 797 requires that low- and medium- risk compounded sterile preparations (CSP痴) be prepared in a 壮uitable・area. The document provides guidance for establishing controls over CSP production and processes. It also includes some recommendations for how to meet the requirements. In a hospital pharmacy context, USP <797> requires the maintenance of ISO Class 5 air quality for the sterile compounding area. This designation, formerly Class 100, allows a maximum of 100 particles per cubic foot. This environmental control is the same level as the typical laminar airflow hood (LAFW) in use in US pharmacies today. The Chapter also allows the use of verified alternative systems in cleanrooms that achieve the same or better level of environmental controls as LAFWs. In addition to the primary engineering control above, USP 797 requires secondary engineering control that provides a buffer zone around the primary mixing area. This buffer zone should be preceded by an anteroom that is a clean area for putting on personnel barriers such as hair covers, gloves and gowns. The class limit for this buffer zone should be demonstrably better than ambient air, providing at least Class 8 air quality. This class, formerly Class 100,000, allows a maximum of 100,000 particles per cubic foot. Baseline testing should be performed in these designated areas to determine the current level of environmental contamination before undertaking construction and redesign projects. Implementing basic cleaning and control steps, coupled with a positive pressure air system, mayresult in a room with less than 10,000 particles per cubic foot. Then, the standard of less than 100,000 particles per cubic foot is achievable by following the simple USP 797 physical facility suggestions.However, in practice there are different options regarding the establishment and maintainance of these production and process controls in the pharmacy. BASIC REQUIREMENTS There are a number of options for meeting the USP 797 guidelines as they are currently described. Three such options (Good, Better, Best) are detailed in the examples below. This guidance is not intended to dictate how a preparation area for low and medium risk CSP痴 must be laid out, but to provide some options for satisfying the USP requirements. The elements below are basic production and process controls that are required for all CSP production areas. Please note that these requirements address environmental control for compounding standard sterile preparations for IV administration. There are separate recommendations for safe handling of hazardous drugs that should be reviewed and addressed prior to undertaking a facility redesign.(8) 1. ISO Class 5 Air Quality in the critical area. Primary environmental control must provide at least ISO Class 5 quality of air to which sterile ingredients and components of CSP痴 are directly exposed.(7) 2. Environmental Controls and Procedures a. ISO Class 8 air quality in the buffer areas b. Area entry c. Materials movement and storage d. Gowning, hair covers, etc. e. Hand washing f. Behavior g. Area clearance between batches h. Area exit 3. Housekeeping Procedure 4. Visual Controls 5. Microbial and Particulate Monitoring "GOOD" STERILE PREPARATION CONTROLS 1. All the Required Items shown above. 2. A Controlled Environment Area of the Pharmacy where CSP痴 are made, ingredients are opened, etc. This area of the pharmacy is not necessarily a separate room, but is isolated and well-marked, using clear visual controls such as floor tape, paint, physical barriers, etc. 3. Laminar Air Flow Workbench(es), Vertical Flow Clean Bench(es), Biological Safety Cabinet(s), or Barrier Isolator(s) certified to provide ISO Class 5 Air Quality. This is where the actual CSP compounding takes place. "BETTER" STERILE PREPARATION CONTROLS 1. All Required Items shown above. 2. A dedicated Controlled Environment Room. This room is closed off from the rest of the pharmacy by standard structural features such as doors and walls. This 努hite room・is isolated, and accommodates all of the items found in #2 of the Required Items above. 3. Laminar Air Flow Workbench(es), Vertical Flow Clean Bench(es), Biological Safety Cabinet(s), or Barrier Isolator(s) certified to provide ISO Class 5 Air Quality. This is where sterile compounding takes place. "BEST" STERILE PREPARATION CONTROLS 1. All Required Items shown above. 2. A positive or negative pressure cleanroom with ISO Class 8 air quality. 3. An anteroom for entry from the outside areas. 4. Airlocks or pass throughs for material movement. 5. Hand-washing facilities. 6. Laminar Air Flow Workbench(es), Vertical Flow Clean Bench(es), Biological Safety Cabinet(s), or Barrier Isolator(s) certified to provide ISO Class 5 Air Quality. This is where sterile compounding takes place. CONCLUSION Most pharmacies will have significant gaps between the USP 797 requirements and their current facilities and standards of practice. The timelines for compliance have been set forth to allow a reasonable period for gap analysis, evaluation and the development of action plans for remediation. A number of steps can be taken in order to immediately improve the practice of sterile compounding, which would reduce the risks of inaccurate and contaminated compounds. Individual facilities should move to address those requirements that would have the greatest immediate impact on CSP quality, then seek guidance where necessary from qualified (certified) consultants with regards to cleanroom design and environmental control prior to modifying existing facilities. ADDITIONAL RESOURCES (1) The ASHP Discussion Guide for Compounding Sterile Preparations. American Society of Health-System Pharmacists. 2004. www.ashp.org. (2) Cleanroom Design: Fundamentals of Design, Testing, and Operation. Whyte, William. ISBN 0471 942049. Wiley Press. (3) Control of Particulate Contamination in Healthcare Manufacturing. Barber, Thomas A. ISBN 1-57491-072-8. Interpharm Press. (4) Frequently Asked Questions About Cleanrooms. Baxa Corporation Technical Paper. Hynes, J. Patrick. (5) HEPA Corporation. www.hepa.com (6) ISO-14644 Family of Cleanroom Standards. (8 documents). www.iso.org. (7) USP, NF, 2004 Chapter 797. United States Pharmaceopeia. www.usp.org. (8) NIOSH Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. Department of Health and Human Services. DHHS (NIOSH) Publication Number 2004-165. September 2004. ゥ 2004 Baxa Corporation |
|
| Contact Information |
| Baxa Corporation Maggie Chamberlin Holben, APR 303.984.9801 or 303.669.3558 maggie@absolutelypr.com http://www.baxa.com |
| Understanding USP 797 Technical Paper An overview of USP General Chapter <797> Pharmaceutical Compounding - Sterile Preparations By Mike Hurst, RPh, MBA | |
| INTRODUCTION USP Chapter 797(1), enacted January 1, 2004, presents the first enforceable standards for sterile compounding. Following years of patient safety recommendations and professional guidelines, the intent of USP 797 is to set forth the procedural and practical requirements for safe compounding of sterile preparations. The Chapter's requirements are applicable in all practice settings where sterile preparations are compounded, raising concern among many facilities regarding the cost and difficulty of compliance. That concern has resulted in numerous symposia and journal articles attempting to bring clarity to the requirements. One article, USP Chapter 797: Establishing a practice standard for compounding sterile preparations in pharmacy・2) published in the September 15, 2004 issue of the American Journal of Health-System Pharmacists provides an excellent historical framework for understanding how USP 797 came about. In addition, the article summarizes the Chapter's major topics and offers 38 references to complete the story. Copies of this article, and many other excellent resource and reference materials are available at the American Society for Health-System Pharmacists・(ASHP) Web site. There, the ASHP Compounding Resource Center(3) brings together information on publications, educational seminars, compliance tools and references regarding USP 797. While understanding the historical background is important, most hospital pharmacists just want to comply with the basic requirements and get on with the business of patient care. This brief paper is intended to help pharmacies get started in that direction. It also discusses USP 797 from a couple of unique angles not necessarily considered in the initial literature published on the subject. GETTING INTO THE FLOW OF USP 797 First, it's important to appreciate that USP 797 was written to improve the compounding of sterile products. But, like any change, it has the potential to be misinterpreted, and thus feared. The biggest misconception about USP 797 seems to be that a sophisticated Cleanroom is required. This requirement has been interpreted in many different ways, and is explained in more detail below. For the most part, USP 797 contains many procedural, training and quality assurance requirements that are not unreasonable for a quality IV operation. In time, USP 797 will be implemented as the US standard for sterile compounding, with ASHP and other industry guidelines following its lead. Once the initial concerns over the cost and difficulty in meeting 797's requirements have passed, patients and staff alike will be better off as a result. Baxa products can be outstanding quality partners in this journey. Our goal is to enable pharmacies to learn how to use Baxa products in compliance with USP 797. THE US PHARMACOPOEIA The USP (US Pharmacopoeia) is a private organization formed in 1820. Current members include many members of accredited schools of medicine and pharmacy, state medical and pharmacy associations, government agencies, consumer organizations and other prestigious health organizations. The standards developed by USP are important for several reasons: 1. The Food, Drug and Cosmetic Act (and thus the FDA) recognizes the USP/NF (National Formulary) as the official compendia of US drug standards. There are hundreds of USP drug standards and all standards numbered less than 1,000 are enforceable by either individual State Boards of Pharmacy, or the FDA. The FDA does not routinely inspect individual pharmacies but may intervene in the case of injuries, a death, or a complaint. 2. USP/NF standards are often used as evidence of national standards in lawsuits. 3. The JCAHO (Joint Commission for Accreditation of Healthcare Organizations) has adopted these standards for use after July 1, 2004. JCAHO accreditation is the most universally recognized standard of US healthcare system quality. JCAHO accreditation is required for reimbursement through the national Medicare program and almost all state Medicaid (welfare) programs. 4. Many State Boards of Pharmacy are adopting USP 797 for their pharmacy inspections. USP Chapter 797 was published in the 2004 edition of the United States Pharmacopeia 27 ・National Formulary 22 (USP-NF). Copies of the chapter may be purchased through ASHP(4) or USP(5). USP: WHAT IT IS Pharmacy rumors abound about USP 797. Clarification on some of the most important topics is below. First, USP 797 is a number of things: 1. Long. It's 18 pages, including 13 using single spacing and a small text font. That's a lot of information to read, but the concepts are not complicated. 2. Paperwork and process intensive. Virtually every significant step of the sterile compounding process is covered in detail. Once again, the major topics are summarized in the September 2004 American Journal of Health-System Pharmacy article. 3. Intended to upgrade pharmacy admixture processes to reasonable precautions. While some pharmacists may disagree with a number of the requirements, the overall tone is proactive, scientific, comprehensive and effective. There is nothing in USP 797 that a pharmacy cannot implement with a reasonable amount of time and resources. 4. Specifies increasing controls based on risk. CSPs (compounded sterile products) are classified into low, medium and high risk categories. Most CSPs prepared with/for Baxa products are in the low and medium risk categories. USP: WHAT IT ISN'T But USP 797 is not some of the things that it's rumored to be: 1. USP 797 does not require sophisticated cleanrooms to be installed. What the guideline does require is environmental controls ・specifically, a separate area for compounding that meets a defined level of cleanliness, and monitoring to ensure that control is maintained. A brief explanation of standards clarifies the actual USP 797 cleanroom requirements. First, there are six levels of ISO (International Organization for Standardization) cleanrooms from ISO Class 3 to ISO Class 8. Three of these are: ISO Class 3 ・equivalent to the former Class 1 designation, allows a maximum of one particle (over 0.5 microns in size for all classes) per cubic foot. This cleanliness level is suitable for the ultimate cleanroom application such as microchip manufacturing, but is not required for pharmaceutical manufacturing or sterile compounding. ISO Class 5 ・(formerly Class 100), allows a maximum of 100 particles per cubic foot; which is the level for the typical laminar airflow hood that is required by USP 797 for the actual mixing area. Mixing IVs in a hood is nothing new in US pharmacies. ISO Class 8 ・(formerly Class 100,000), allows a maximum of 100,000 particles per cubic foot. This level is required for an IV preparation area/IV room. There are other issues recommended in the Chapter, such as an ante room for dressing, etc. but the Class 100,000 mixing area is the primary environmental control requirement. Implementing the most basic steps of straightening up an IV room, coupled with a positive pressure air system, will result in a room with less than 10,000 particles per cubic foot. Getting an IV room to less than 100,000 particles per cubic foot is achievable by following the simple USP 797 physical facility suggestions. The first step is getting a baseline on your existing facility to determine what remediation steps, or facility and procedural redesign, will be required to meet the environmental controls above. The net result of the USP 797 guidelines is that sterile mixing take place in a properly maintained laminar airflow hood (ISO Class 5) situated in a relatively clean room (ISO Class 8). For most pharmacies, this is neither difficult or unreasonable. In some cases, individual interpretations of this requirement have made it seem more onerous. 2. USP 797 is NOT a radical departure from what most admixture programs are already doing. There are basic steps in quality sterile compounding that many inpatient pharmacies have unfortunately not had the time, or interest, to implement. Regulatory agencies such as the FDA and State Boards of Pharmacy have long recognized this need. USP 797 simply puts the requirements in a format that inspectors can check against. 3. USP 797 cannot be fully met by outsourcing. Legitimate first doses are not covered by USP 797 and other doses can be outsourced. But almost any pharmacy will still need to make many doses such as those subject to change, short-expiration drugs, some antineoplastics etc. that are not candidates for outsourcing. Other expensive and specialized drugs may be hard to outsource, also. Sterile compounding activities can be minimized through an outsource arrangement, but not entirely eliminated. This means that nearly all hospital pharmacies will still have to meet the requirements of USP 797. 4. Isolators alone will not ensure compliance with USP 797. Using an isolator for sterile compounding handles only part of the requirements for USP 797. Issues such as process validation, training, expiration setting, product quality maintenance after the CSP leaves the pharmacy, caregiver training, patient monitoring, QA program, etc. remain the same as for products compounded in standard laminar flow hoods. The special requirements for cleaning the isolator itself and for cleaning materials entering the isolator make this a demanding alternative to standard pharmacy flow hoods. Additionally, many users find isolators physically difficult to work in and inappropriate for medium-to-large institution workloads. WHAT'S NEXT? Compliance with USP 797 will be achieved through the completion of steps on a timeline that stretches out to January 2008. The requirements allow pharmacies to plan appropriately for compliance, understanding that changes of this magnitude will not be accomplished overnight. JCAHO surveyors began surveying facilities for compliance with Chapter 797 on July 1, 2004. Many of the requirements are equivalent to current elements of performance of the 2004 Joint Commission standards. Current compliance to these will be evaluated and scored in JCAHO reviews. Other areas of Chapter 797 will be evaluated but not scored. The October 2004 issue of Joint Commission Perspectives listed the five items that the USP 797 advisory group recommends that organizations focus on for compliance. This list, repeated below, recognizes that the task of developing a comprehensive plan for USP 797 compliance is a daunting one. While all components of the Chapter must be addressed for compliance, these priority activities will allow organizations to make the most significant progress towards achieving its goal of improving the quality of sterile compounded products. 1. Personnel training and evaluation (that is, competence assessment) 2. Beyond-use dating and labeling 3. Verification of automated compounding devices 4. Finished preparation release checks and tests 5. Aseptic technique USP 797 represents a profound change for the profession of pharmacy. The key is using aseptic technique with the right equipment in an environment that's appropriate. Baxa is working on a number of consultive strategies and tools to help our customers meet the compliance challenges of USP 797 as easily as possible. The company is committed to providing the right equipment, along with the training and assessment tools, to meet patient safety and sterile compounding requirements. KEY COMPLIANCE DATES AND ACTIVITIES Summarized below are the key dates and activities for USP 797 compliance. Please refer to full document for details. Pharmacies should have basic policies for aseptic technique, finished product testing, patient monitoring, and adverse drug reaction (ADR) reporting in place currently. Immediate attention should be paid to high-risk level product sterility. That said, the most urgent initial task for USP 797 compliance is the completion of a gap analysis. This document details the current state of the pharmacy against the end state, or compliance with USP 797, to identify the differences or gaps. From that analysis, an action plan can be formed to prioritize the gaps and develop options for compliance. January 2005 ・The Gap analysis and an initial action plan for each section must be completed by January 1, with interim measures for personnel performance training and testing set up. This is the first major milestone for most organizations. Action plans are expected to have realistic timeframes for completion, with the understanding that full compliance will not be accomplished quickly. Several templates available for performing this gap analysis. The International Journal of Pharmaceutical Compounding offers a reasonably priced gap analysis template on CD.(7) Two additional options are available through the ASHP. The first, the 797 Compliance Advisor is an industry-sponsored tool that offers downloadable checklists.(8) The second is a more comprehensive, Web-based tool that takes users through the step-by-step questions to complete the analysis.(9) Check the sources at the end of this paper for Web links to these templates. July 2005 ・Renovation plans for physical site must be completed. Equipment and personnel training, and all operational policies and procedures and the quality assurance plan should be in writing. Standard operating procedures (SOPs) for personnel and equipment need to be in place and operational. January 2006 ・Formal quality assurance plan should be in place and operational. January 2008 ・Physical site changes should be complete, with sterile compounding fully compliant with USP 797. SOURCES CITED (1) USP General Chapter <797> Pharmaceutical Compounding ・Sterile Preparations. United States Pharmacopeia. 2004. (2) Kastango E. and B. Bradshaw. American Journal of Health-System Pharmacy. Volume 61, Number 18. September 15, 2004. (3) The ASHP Compounding Resource Center, http://www.ashp.org/SterileCpd/ (4) American Society for Health-System Pharmacists. www.ashp.org. (5) United States Pharmacopeia. http://store.usp.org). (6) ASHP 797 Compliance Advisor http://www.797complianceadvisor.com/ (7) International Journal of Pharmaceutical Compounding. http://ijpc.com/products/ProductDescription.cfm?PID=141 (8) http://www.ashpbestpracticessat.com/797.html ゥ2004 Baxa Corporation | |
ABOUT THE AUTHOR Michael Hurst RPh, MBA worked for 18 years at Swedish Medical Center in Seattle, Washington in operational management, including positions as IV Supervisor and Assistant Director of Pharmacy. His implementation of a syringe infusion system in 1984 had national implications. For the next 9 years Mike wrote, spoke, consulted and acted as a reference site for syringe infusion installations across the country. Mike moved to industry full time in 1994, joining Baxa Corporation as Vice President of Infusion Systems. His job duties have included customer support for syringe infusion system installations, new business and product development roles, and professional services support for various Baxa pharmacy and nursing product lines. Mike is currently consulting with a hospital system in the development of a comprehensive USP 797 compliance template that can be applied in other hospital pharmacies | |
University of California Uses Technology to Tackle Rising Healthcare CostsCalifornias 2nd largest employer selects CompassCares Clinical Information System.
Chicago, IL (PRWEB) January 26, 2006 -- The University of Californias (UCs) Office of the President selects CompassCares Clinical Information System, which will be provided to its occupational health clinics on a system wide basis. CompassCare provides software to manage healthcare information and delivery.
A top priority for UC is to ensure that all employees have access to quality healthcare when they need it. Technological innovation helps us advance the delivery of care while stemming the tide of rising costs, says Dan Nicholson, Workers Compensation Manager, UC Office of the President.
The State of California has seen workers compensation (WC) costs more than triple from 1995 to 2003. Total medical treatment costs are estimated to be 50 to 100 percent higher in WC than treatments paid for by private health insurance. Although medical costs have decreased with recent reforms, the overall cost of workers compensation in California remains significantly higher than in other states.
As the 2nd largest employer in California with more than 175,000 faculty and staff, it is important that we take proactive measures to ensure our peoples access to high quality care, says Nicholson. CompassCare enhances our ability to monitor and measure performance system wide, increasing our visibility into the entire care process. It will help us standardize clinical documentation electronically, capture information on a real-time basis, transmit appropriate levels of information to the correct parties (e.g., claims administrator), and automate clinical and operational functions using a rules-based engine.
UC comprises 10 campuses and 5 medical centers. The Office of the President is responsible for UC's system wide activities and programs including the coordination of all workers compensation claims made throughout the UC system. The CompassCare system will be used by UC to link together its Occupational Health clinics on a common, electronic platform, creating seamless networking and information flow.
The CompassCare clinical information system integrates practice management, EMR, billing and communication processes on top of a rules engine driven architecture all accessible from a secure, HIPPA compliant, web-interface.
Effectively managing the delivery of Occupational Healthcare services is paramount for employers like the University of California who serve a broad patient community. We designed CompassCare with the intent of improving the delivery of care on a massive scale. This is being validated at UC as it is with several other hospital systems that use our software, said Rick Valentine, CEO of CompassCare Inc.
The CompassCare system helps hospitals reduce the costs associated with processing claims, ensure compliance with regulations, eliminate redundant data entry, manage the delivery of care, and improve communication flow between key stakeholders such as the healthcare provider, the employer and the insurer, all to ensure the injured worker gets the required treatment quickly and efficiently, says Valentine.
UC represents Chicago-area CompassCares 3rd customer in California, others include Dameron Hospital in Stockton, CA and Sutter Health based in Sacramento, CA.
About University of California
UCs ten campuses at Berkeley, Davis, Irvine, Los Angeles, Merced, Riverside, San Diego, San Francisco, Santa Cruz and Santa Barbara. The UCs 5 medical centers and 10 health centers comprise one of the largest health care systems in the state, and one of the most respected in the country. Each year the University provides care to more than 135,000 inpatients, 239,000 emergency room visitors and more than 3.6 million outpatients. In 2004, the UCLA and UCSF medical centers were ranked fifth and sixth, respectively, in the entire by U.S. News and World Report.
About CompassCare
CompassCare Inc. provides occupational healthcare stakeholders (employers, care providers, and TPA/ case managers) an integrated management system that connects all parties together in "real-time via the Internet. It provides instant access to HIPAA-compliant information on an injured worker so all parties have the tools they need to manage the information and activity associated with workers' compensation. The result is improved quality of care and better financial and operations management. With more than 25 million electronic medical (patient) records accurately processed to date, CompassCare is one of the leading suppliers of healthcare information technology. The following are copyrights of CompassCare: CompassCare, MedTRAK, FasTRAK, ClaimTRAK, CaseTRAK, For more information please visit: www.compass-care.com.
Media Contact:
Stewart Dixon
847.604.9800
# # #
Press Contact: Stewart Dixon
Company Name: CompassCare
Email: email protected from spam bots
Phone: 847-604-9800
Website: www.compass-care.com
Wisdomatics Launches Health Industry News - Comprehensive Resource for Medical and Pharma SectorsWisdomatics, publishers of the successful consumer health websites BreakThroughDigest.com and Search Cancer.com, announces the launch of a new business information portal for the medical industry: Health Industry News.
Seattle, WA (PRWEB) January 26, 2006 -- Wisdomatics, publishers of the successful consumer health websites BreakThroughDigest.com and Search Cancer.com, announces the launch of a new business information portal for the medical industry: Health Industry News (www.healthindustrynews.com).
"This website is about the business of medicine", says Wisdomatics president and executive producer, Gary Bryant. "There are financial information sources out there that offer highlights of the health industry, and there are consumer health sites that allude to the business side of medicine. But Health Industry News is nothing but Health Industry News."
Wisdomatics is no stranger to the Web and health content in particular. Launched in 2003, their flagship website Breakthrough Digest now receives millions of visitors each year.
"Consider the challenges this industry faces today: drug companies have a public image problem, a deepening health insurance crisis as more and more employers cut health benefits, a nursing shortage, dissatisfaction with the new federal prescription drug plan, and of course, product safety." Says Bryant, "This is a fragmented business sector that screams for visionaries."
One feature to be introduced in April of 2006, Health Industry Leaders, will present editorial content written by the leadership of the industry. Health Industry Leaders will be an opportunity for a company's visionaries to provide high-level perspective on the issues facing the healthcare industry today- a perspective that can only come from a company's unique position in the marketplace.
Other site highlights include daily news updates, interactive event scheduling, a sizeable resource directory and additional features available to registered users. The entire site's offerings are free. Health Industry News can be found on the Web at http://www.healthindustrynews.com
Wisdomatics is a web site publishing enterprise. Since 1994, has created, developed and managed a number of award winning web sites including BreakThroughDigest.com and Search Cancer.com.
# # #
Press Contact: Gary Bryant
Company Name: WISDOMATICS
Email: email protected from spam bots
Phone: 360 547 1339
Website: http://www.healthindustrynews.com
Glenn Galloway, CEO for Healthia Consulting, stated: "The annual HIMSS conference is the place to be for an organization like Healthia Consulting. It brings the key industry players right to us; those who can make the buying decisions and are ready to buy. When they stop by our booth, we can talk one-on-one with them about their needs and how Healthia Consulting can help them meet those needs. We would never be able to see as many high-level decision makers otherwise."
The HIMSS conference attracts more than 22,000 attendees annually, making it one of the largest healthcare IT and management systems conference in the world. Attendees who visit the conference participate in education sessions and networking events, in addition to visiting the exhibits. The 2006 conference takes a knowledge-based focus, with more than 300 education sessions and seven symposia, including five new sessions: Pre-Nursing Informatics, Clinical Engineering, Pay-for-Performance, Pharmacy and RHIO, in addition to the Nursing Informatics and Physician symposia so popular at HIMSS 2005. The Interoperability Showcase returns in 2006 with groundbreaking demonstrations that utilize cutting-edge technology and standards to demonstrate interoperability in an interactive environment. Attendees will be able to create, track and manage virtual electronic health records and experience interoperability advances across both acute and ambulatory care environments.
Among the speakers lined up for the 2006 conference are keynoters secretary of Health and Human Services, Michael Leavitt (invited), national health information technology coordinator, Dr, David Brailer, Virginia Governor, Mark Warner, and Intel board chairman, Craig R. Barrett, as well as a number of leading healthcare IT industry and business speakers.
ABOUT HEALTHIA CONSULTING
Healthia Consulting, Inc. is a privately held national healthcare consulting firm that offers management advisory and solution delivery services for healthcare provider, payer and life sciences organizations. Founded in 1998, the company has three regional offices in Chicago, Minneapolis and Denver and a client roster that includes the nation's most prominent healthcare organizations. For more information, visit www.healthiaconsulting.com.
ABOUT HIMSS
HIMSS (Healthcare Information and Management Systems Society) is the healthcare industry's membership organization exclusively focused on providing leadership for the optimal use of healthcare information technology and management systems for the betterment of human health. Visit www.himss.org for more information.
| StoneBridge Group | |
|---|---|
| Source: via Business Wire Updated 01/10/2005 by company | |
| Headquarters: | Minneapolis, MN |
| Website: | http://www.stonebridgegroup.com |
| CEO: | Glenn Galloway |
| Employees: | 45 |
| Organization: | Private |
Dynamic Healthcare Systems Debuts ManagingMedicare.comIndustry site designed to serve medicare professionals.
Irvine, CA (PRWEB) January 25, 2006 -- Dynamic Healthcare Systems, a provider of innovative solutions for Medicare-focused health plans, today announced the creation of ManagingMedicare.com (http://www.managingmedicare.com), a Medicare industry web site that offers analysis, expertise, current information, discussions and collaboration between professionals who are committed to the success of the ever changing Medicare industry.
As new guidelines and regulations set forth by the Medicare Modernization Act of 2003 are rolled out for implementation, Medicare-related businesses need a forum for up-to-date analysis and information to help them streamline their transition and adoption of the new rules, said Ken Stockman, Founder and CEO of Dynamic Healthcare Systems, Inc. ManagingMedicare.com is a collaborative site that tracks trends, issues, ideas and best practices.
ManagingMedicare.com has enlisted industry experts and leaders to contribute content on a regular basis. Collaboration between professionals who manage Medicare programs is critical to the success of providing quality health care to the elderly and disabled. ManagingMedicare.com is just one place where cooperation and the exchange of information and ideas can take place.
About Dynamic Healthcare Systems
Dynamic Healthcare Systems, Inc. was founded on delivering comprehensive solutions for Medicare Advantage health plans and MSOs striving to succeed amid new and evolving regulatory requirements. Headquartered in Irvine, California, the company brings world-class innovations to middle market companies serving the Medicare population. Dynamic Healthcare Systems can be reached at (949) 975-1877. www.dynamichealthsys.com.
Contact:
Dynamic Healthcare Systems
Media Relations
Jay Baker
Phone: 805.906.7327
Web: http://www.dynamichealthsys.com
# # #
Press Contact: Jay Baker
Company Name: DYNAMIC HEALTHCARE SYSTEMS INC.
Email: email protected from spam bots
Phone: 805.906.7327
Website: www.dynamichealthsys.com
C.A. Short Assembles New Marketing Taskforce to Focus on Healthcare IndustryC.A. Short has formed a new marketing taskforce to develop an employee recognition program exclusively for the healthcare industry. The new program, the Preferred Recognition Program (PRP), will offer unique benefits like plateau pricing, a more diverse range of gifts and a dedicated customer service professional.
Shelby, NC (PRWEB) January 23, 2006 -- C.A. Short Company, a leading provider of employee recognition solutions, today announced the formation of a new marketing taskforce with the sole responsibility of developing, designing and marketing an employee recognition program exclusively for the healthcare industry.
Healthcare is an extremely diverse yet employee conscious industry that appreciates and recognizes people for their hard work and commitment. This is the perfect client demographic for C.A. Short since research proves overwhelmingly that 3 out of 4 companies that rate its employee appreciation and loyalty rates as High choose C.A. Short as their recognition provider, said C.A. Short Company President, Chuck Davis.
The new exclusive healthcare recognition program, the Preferred Recognition Program (PRP), will be specifically designed to celebrate diversity by including a choice of presentation box or folder, gift brochure, personalized certificate and custom award in any of 24 different combinations.
Some of the additional unique benefits the healthcare industry can expect to see with the new Preferred Recognition Program (PRP) are plateau pricing, a more diverse range of gifts and a dedicated dependable customer service professional.
The plateau-pricing model C.A. Short is offering is ideal for industries like healthcare that have a fixed budget for their Service Award Program. The total cost is set at the start of the program based on each organizations specified budget and never exceeds or wavers from that set price.
The plateau pricing model is unique to C.A. Short, designed by our customers and offering numerous advantages for our customers program and budget, said Davis. Other recognition providers have a tendency to build their programs on the old average pricing paradigm, which is misleading, and in many cases, unethical. Organizations are tricked into buying a program based on a proposed average total price and then sent into a budgetary roller-coaster when they are invoiced for their items. Administrators then have to borrow against the following years budget or worse, are forced to ask their boss for additional funds at the end of the fiscal year. That is the last thing we want our customers to have to do. Davis added.
Another benefit, the larger number of gift choices, offers the healthcare industry and their diverse workforce a much better selection compared to the older, more traditional Service Award Programs that offer as few as 10-15 choices that very few people really want or need. C.A. Shorts new Preferred Recognition Program (PRP) offers nearly 100 diverse lifestyle items in each level guaranteed to WOW administrators and associates alike.
About C.A. Short
Established in 1937, C.A. Short (www.cashort.com) is a leading full-service recognition company providing Years of Service, Safety Incentive, Performance Recognition, and Holiday Gift Programs for companies and organizations in the United States and around the world. For more information on the benefits of the Preferred Recognition Program (PRP) or to find out how you can enhance your recognition investment, contact C.A. Short for a free consultation.
# # #
Press Contact: Cassie Cooper
Company Name: C.A. SHORT COMPANY
Email: email protected from spam bots
Phone: 800-535-5690
Website: www.cashort.com
AlliReport.com Provides Latest News About Over-the-Counter Alli, Low-Dose XenicalAlliReport.com, an independent news site published by Medical Week News, Inc., provides the latest news about Alli, trade name for low-dose Xenical. Alli, which is half the strength of prescription Xenical (orlistat), is seeking approval to become the first prescription weight-loss drug to be sold over-the-counter. Medical Week News also publishes the highly rated site, AcompliaReport.com, reporting on the new prescription weight-loss drug, Acomplia (rimonabant).
Washington, DC (PRWEB) January 23, 2006 -- Medical Week News, Inc., publisher of the highly rated Acomplia Report (http://www.acompliareport.com), announced it has launched a new guide to weight-loss drugs called Alli Report (http://www.allireport.com) to cover latest news about the new over-the-counter version of the prescription weight-loss medication Xenical (orlistat).
With Alli awaiting U.S. Food and Drug Administration (FDA) approval to be sold without a prescription, we believe a growing number of Americans will soon be searching for independent, objective news and information about the benefits and risks of taking this low-dose version of Xenical, said Milton R. Benjamin, publisher of Alli Report (http://www.allireport.com).
We intend to provide all the positive and negative expert opinions on the use of Alli just as our other obesity publication, Acomplia Report (http://www.acompliareport.com), provides all the news about the prescription drug rimonabant as it makes its way through the FDA and European approval processes, Benjamin added.
The Alli Report (http://www.allireport.com) will be updated daily by Medical Week News, and will keep readers fully informed on the FDA approval process, and when this over-the-counter version of low-dose Xenical will be available to the public.
# # #
Press Contact: Milton Benjamin
Company Name: MEDICAL WEEK
Email: email protected from spam bots
Phone: 772-559-4187
Website: www.allireport.com
FDA Raises Warning Flags on Over-the-Counter Sale of Low-Dose Xenical
The U.S. Food and Drug Administration (FDA) staff has raised a variety of warning flags in advance of an advisory committee meeting set for Jan. 23rd to consider GlaxoSmithKline's petition to sell a half-dose version of the diet drug Xenical (orlistat) without a prescription. The FDA staff, in documents released on Jan. 19th, questioned whether the proposed six-month treatment with the over-the-counter version of the drug would be beneficial for a "chronic" condition like obesity.
The staff's comments were being scrutinized particularly closely by those awaiting an FDA decision on whether to approve the new prescription weight-loss drug Acomplia (rimonabant).
While the FDA reviewers did not dispute that the new version of Xenical helped more patients lose weight than those on placebo, they said "there is no evidence presented that a modest, transient weight loss due to orlistat will afford any long-term clinical benefit through either a change in behavior or a reduced risk of serious clinical diseases manifested by being overweight.
"It is difficult to define the clinical benefits of short-term treatment with orlistat," the FDA said. "Although not studied by the sponsor, it is well known that once weight-loss treatment is stopped, lost weight is quickly regained and improvements in co-morbidities become undone."
Patients in clinical trials of Acomplia achieved impressive weight-loss gains in the first year of taking the drug, but for the most part regained the weight in the second year if they stopped taking it.
In addition, the FDA staff expressed concern that the OTC version of Xenical, which would be marketed under the name Alli, might be taken by some type 2 diabetics (many of whom are overweight) and other patients that did not understand the risk after reading the label.
In a study cited by the reviewers, only one-third of those taking diabetes medication correctly stated that they should not use orlistat, and only half the people taking the blood-thinner warfarin correctly understood that they should not use it.
If the FDA, which generally follows the counsel of its advisory committees, ultimately approves Alli, it will be the only FDA-endorsed weight-loss drug available without a prescription.
Report Says Acomplia Still Must Overcome "Skepticism About Its Side Effects"
An article set for publication in the respected journal, Nature Medicine, says that while Acomplia (rimonabant) may turn out to be the "Prozac of obesity," it still faces the challenge of overcoming "skepticism about its side effects." The article notes the troubled past of obesity drugs, ranging from misuse of amphetamines to the "fen-phen debacle of the mid-1990s, when one component of the popular pill combination was foundbut only after several years on the marketto cause irreversible heart valve damage."
While the developer of Acomplia, Sanofi-Aventis, has two years of safety data from clinical trials that concluded last year, U.S. and European regulators currently weighing approval of the drug are thought to still be concerned about the possibility of adverse effects developing during long-term usage.
Participants who lost significant amounts of weight in clinical trials of Acomplia regained the weight when they stopped taking the pill, suggesting that to keep weight off, people will have to continue on Acomplia indefinitely.
The most common side effects reported during the Acomplia clinical trials were nausea, dizziness, diarrhea and joint pain, which researchers described as "mild and transient."
But Nature Medicine reports that when drugs target the central nervous system to control appetite, "how they influence peripheral function only comes out after people have been on the drugs for a period of time," according to Jeffrey Bland, president of Metagenics, a California-based maker of nutritional products.
The journal also took note of reports by researchers that ten participants taking Acomplia in the clinical trials dropped out because of depression, compared to two participants in the clinical trials taking placebos.
"In a 2005 survey of 142 doctors conducted by Decision Resources, a Massachusetts-based pharmaceutical market research firm, more than 80 percent listed depression triggered by the drug as their primary concern; insomnia ran a distant second at 45 percent," the journal reported.
Gor a Health Insurance Beef or Question? New State Health Insurance Laws and Regulations Directory Can Help |
| Press Release by: Benefits Boutique |
| Published on openPR 01-20-2006 09:03 am - CET |
FLAVORx Enhances Treatment Options for Pediatric Oncology PatientsBecause of the struggles that young cancer patients face on a day to day basis during and after treatment, FLAVORx is dedicated to defining methods in which they can best accommodate their needs to make their situation that much more bearable. Working with several cancer-related medications and consumer responses, FLAVORx has discovered flavorings that improve several cancer medications' taste most effectively, and therefore improves patient quality of life.
Bethesda, MD (PRWEB) January 19, 2006 -- It is estimated that approximately 12,400 children in the United States are diagnosed with cancer each year. The most common childhood cancers are leukemia, lymphomas, brain tumors and bone cancers. The frequency of cancer diagnoses has risen since the 1970s. In each individual case, cancer patients and their families must endure the pain, uncertainty and disruptions caused to their lives as a result of the diagnosis. Recognition of the needs of these pediatric oncology patients and the opportunity to improve the quality of their lives has led FLAVORx to dedicate a targeted investigation on how they can best serve the needs of childhood cancer patients.
The chemotherapy, doctors exams, constant discomfort of their condition and the countless medications these children must tolerate, is more than even the strongest adult could endure. Beyond the physical and medical changes to a childs lifestyle, diagnosis and treatment also cause feelings of fear, anxiety, anger, guilt, sadness and depression. Therefore, any way of making these childrens lives a little easier, a little less painful and a little less traumatic is what FLAVORx strives for. Succeeding in this manner is what sets FLAVORx apart as a company dedicated to understanding the needs and situations of all children.
Medications used during cancer treatment are essential to alleviate or eradicate the signs of cancer from the body and can be classified into two groups: antineoplastic (cancer-fighting) or immuno-suppression (lessening the bodys reaction). These include drugs that can prevent infection, like antibiotics, or drugs that treat side effects such as nausea and pain. FLAVORx testing and research with children has shown that some flavors mask the existing tastes of certain medications better than others. Of the following common cancer medications, here are some of the most effective flavors:
1. Zofran (for nausea associated with chemotherapy)- Raspberry, Natural Orange, Bubblegum
2. Phenergan (for nausea associated with chemotherapy)- Grape, Sour Apple, Peaches and Cream
3. Acyclovir (to prevent viral infections)- Orange Cream, Banana, Cherry
4. Septra/Bactrim (to prevent some types of pneumonia)- Grape, Bubblegum, Watermelon
5. Vancomycin (an antibiotic)- Vanilla, Strawberry Cream, Grape/Bubblegum
6. Roxanol (to relieve pain)- Grape, Raspberry, Orange Cream
Because FLAVORx flavors are inert, non-allergenic, sugar-free, alcohol-free, very concentrated, as well as gluten and casein-free, they do not affect the efficacy of the medication and also comply with any specific dietary restraints (to reduce the risk of infection from food) that many oncology patients must follow.
Many years ago, a father came to FLAVORx with a problem. His young son had an inoperable brain tumor and was on a very strict regimen of medications. In anticipation of the medications taste, the young boy would become nauseated hours before he had to take them everyday, and simply could not keep them down. With no foreseeable solution, his parents were told if he couldn't ingest the medications necessary for his survival, they would have no choice but to return him to the hospital and administer the medications intravenously. Needlessly readmitting their son to the hospital would add unnecessary strain and suffering to an already unbearable situation. The family knew he would only be comfortable in a home setting, not in a cold, sterile hospital. They finally found FLAVORx and Kenny asked the entire family to come in to see how he could help. Kenny asked the little boy to name his favorite flavor, and without hesitation, he responded Reeses Peanut Butter Cups. Kenny created a formulation using a combination of peanut butter and chocolate flavoring to pair with each of his medications.After that the young boy was able to take all of his medicine without opposition. Sadly, he only lived for eight more months but his final months were spent at home with his family and those that loved him, surrounded by familiarity. Kenny recalls, Knowing that we were able to bring this child a little happiness at the end of his life is a feeling that I will never forget. It was a feeling of triumph over an otherwise cold world that for the most part didnt do all it could to help a little boy, and value the importance of his life. I will always remember him and feel we succeeded by helping him and his family. After this, I vowed I would never let another childs health and happiness fall by the wayside if I could help it.
It is extremely important that children with compromised immunity, as in the case of cancer, take all medications prescribed by their physicians as they are precisely directed. FLAVORx has improved treatment quality in administering medicines by alleviating the unnecessary strain, trauma and more importantly, ramifications of medicinal non-compliance by improving the taste of unpalatable medications. FLAVORx President and CEO, Kenny Kramm, has brought increased pediatric oncology awareness to his company, as well as a heightened dedication to patient needs. FLAVORx offers 42 scientifically developed and safety-tested flavors to cover both over-the-counter and prescription medications and is available at most pharmacies nationwide.
For more information, please contact Teresa Chen at 800.884.5771, extension 234.
# # #
Press Contact: Teresa Chen
Company Name: FLAVORX, INC.
Email: email protected from spam bots
Phone: 240.223.0953
Website: www.flavorx.com
Carmel Pharma, Inc. to Market and Distribute PhaSeal®, the Only Clinically-Proven Closed System Transfer Device Available TodayAt the beginning of 2006, Carmel Pharma, Inc. applies its passion and undivided resources to the distribution and education of their own product, PhaSeal®--the only "clinically-proven" closed system transfer device available today. PhaSeal's unique design "contains the drug" which helps prevent occupational exposure to hazardous drugs in health care settings--a call to action required by The National Institute for Occupational Safety.
Columbus, OH (PRWEB) January 18, 2006 -- Carmel Pharma began to market and distribute PhaSeal® from its own company, Carmel Pharma Inc, based in Columbus Ohio as of January 2006.
PhaSeal is the only "clinically proven" closed system transfer device on the market today. It's unique design is meant to prevent environmental contamination and help protect healthcare employees through the preparation, administration and waste handling of hazardous drugs.
The National Institute for Occupational Safety (NIOSH) states that "working with or near hazardous drugs in health care settings may cause skin rashes, infertility, miscarriage, birth defects, and possibly leukemia or other cancers," quotes David Schneider, President of Carmel Pharma Inc. "The PhaSeal System contains the hazardous drug which prevents enviromental contamination, therefore providing healthcare workers a safer working environment. As the manufacturer, our sole focus is to continue to educate and be a valuable resource on this important safety issue."
PhaSeal's double membrane provides dry connections between system components and it's expansion chamber ensures aerosols and vapors are contained and neither over pressure or under-pressure occurs duing drug preparation.
PhaSeal was launched in the US in December of 2000 and today, more than 400 leading cancer facilities, such as MD Anderson, University of San Francisco, Standford and Texas Childrens Hospital have contributed to PhaSeal's outstanding growth. Carmel Pharma has recently been placed on the Deloitte´s Fast 500 EMEA List.
If you have questions or want more information on ordering PhaSeal, please contact Carmel Pharma, Inc. at
866-487-9250 or 614-841-0504.
Contacts:
Christine Crooks, Marketing Director Carmel Pharma, Inc.
Direct: 866-487-9250 ext. 202
Agneta Ekblad, VP Oncology Solutions Carmel Pharma Inc. Direct: 858-220-3583
David Schneider, President Carmel Pharma Inc.
Direct: 866-487-9250 ext. 201
# # #
Press Contact: Christine Crooks
Company Name: CARMEL PHARMA, INC.
Email: email protected from spam bots
Phone: 614-841-0504
Website: www.phaseal.com
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
New Technical Report Outlines ICT and the Future of Healthcare in CanadaA newly released technical report examines the role that ICT will play in the future of health systems in Canada and analyzes in-depth the status and future of the Canadian health industry in relation to the healthcare ICT market.
Saskatoon, Canada (PRWEB) January 18, 2006 -- Bankix Systems Ltd has released its new 271-page technical report, ICT and the future of healthcare in Canada. This technical report examines the role that ICT would play in the future of health systems in Canada. It analyzes in-depth, the status and future of the Canadian health industry in relation to the healthcare ICT market. It explores investments and market opportunities in the health ICT industry, and discusses the interplay of factors shaping the future of the health industry in Canada, including the role that ICT would play in the sustainability and future direction of the countrys health systems.
Canadas health system is evolving, and healthcare ICT is an integral part of this evolution. This technical report presents a comparative analysis of healthcare ICT initiatives, their financing, and implementation at federal, provincial, and territorial levels, and the underlying dynamics of the drivers of the initiatives at these various levels. The goal of this analytical approach is to facilitate an appreciation of the issues fundamental to current healthcare ICT spending and to anticipate those germane to future investments in health ICT. Such appreciation would be invaluable to software vendors and ICT companies interested in the Canadian health ICT market.
Healthcare professionals, Hospital CEOs and CIOs, government agencies, other healthcare stakeholders, including members of the public interested in how healthcare ICT is shaping the future of healthcare services in Canada would also find this technical report useful.
Bankix Systems Ltd is a Canadian healthcare ICT consulting company that publishes online articles, reports, market, and industry analyses, and books on healthcare ICT. Kindly visit our website at www.bankixsystems.com
###
Press Contact: George Obikoya
Company Name: Bankix Systems Ltd.
Email: email protected from spam bots
Phone: 1-306-441-6601
Website: www.bankixsystems.com
Medicare Part D News & Resource Site ReleasedMedicare news and resource site just released to help consumers stay informed about the recent and ongoing changes for Medicare policies and the recent "Part D" Prescription Drug Plan.
Tampa, Florida (PRWEB) January 18, 2006 -- Ongoing confusion created by the recently released Medicare "Part D" prescription drug plan stemmed a new website to help cut through the confusion and keep consumers informed about Medicare policies.
The latest revision to Medicare that has seniors everywhere scrambling to try and understand how it impacts their lives is "Part D." Medicare Part D was enacted to help seniors make prescription drugs more affordable because many could not keep up with the rising costs of their daily regimen.
Current members of the Medicare program have a 6 month enrollment extension and the plan is expected to help more than 40 million seniors across the nation. The current deadline to enroll in a program is May 15, 2006 and if late their are some hefty penalties, one of which includes the loss of health benefits from employers.
Medicare-News.com is aggregating the latest breaking news and resources to help consumers understand Medicare policies, updates, and revisions so they can make informed decisions for their health care and medical insurance needs.
To find the latest breaking news and information just visit Medicare-News.com.
http://www.medicare-news.com
The site also offers a convenient RSS feed that you can plug in to news readers to make the content even more convenient.
###
Press Contact: Jimmy Ellis
Company Name:
Email: email protected from spam bots
Phone: 352-256-4480
Website: http://www.medicare-news.com
An ICT Perspective on Private v. Public Healthcare in CanadaThis e-book examines the role of ICT in how the private/public health system debate in Canada plays out.
Saskatoon, Canada (PRWEB) January 15, 2006 -- Bankix Systems Ltd has released its new 68-page e-book, An ICT perspective on Private v. Public Healthcare in Canada. The e-book examines a kaleidoscopic health issue in Canada with a technology paradigm. It discusses the pros and cons of public and private health systems, and analyzes differing views on the debate.
It examines the effectiveness of the current health system and its challenges, if a parallel private healthcare system would be more effective in reducing wait times, and the overall costs of running a public versus a private health system. It also examines broader views regarding the interplay of political, social, economic, and technology forces in the success or otherwise of any health system, including in the financial rearrangement, insurance regulation and risk, and other issues that a shift to a private health system would engender.
The role that ICT plays in improving the efficiency and effectiveness of healthcare delivery is no longer in doubt. The e-book explores the differences in approaches to ICT implementation between publicly vis-à-vis privately financed health systems and the consequences of these differences for their survival, competitiveness, and sustainability. It examines pertinent questions that arise thereof and seeks to provide answers to these and other important questions relevant to the debate.
Doctors, nurses, and other healthcare professionals, hospital CEOs, government agencies, software and ICT vendors, all other healthcare stakeholders, and members of the public interested in the private v. public health debate would find this e-book delightful to read.
Bankix Systems Ltd is a Canadian healthcare ICT consulting company that publishes online articles, reports, market and industry analyses, and books on healthcare ICT. Kindly visit our website at www.bankixsystems.com
###
Press Contact: Dr. George O. Obikoya
Company Name: BANKIX SYSTEMS LTD.
Email: email protected from spam bots
Phone: 13064416601
Website: www.bankixsystems.com
Mail-order prescriptions accounted for more than $40 billion of total U.S. prescription sales in 2004. Mail-order is a growing area because of the cost savings and convenience associated with it. Employers are turning to both incentive and mandatory programs. Employers typically save 10-20 percent off retail drug costs. These cost savings are achieved because the primary operators of mail order pharmacies- pharmacy benefit management companies-can purchase drugs in bulk and pass on their savings to employers. Such bulk savings are particularly important in the purchase of maintenance medications. Maintenance drugs account for the majority of US prescription drug spending and, as such, can account for a high percentage of an employers medical costs. With this in mind, more and more employers-approximately 22 percent today- are requiring their employees to use mail order services to fill their prescriptions. Large employers especially, such as Microsoft and General Motors, are turning to mandatory mail-order benefits for employees. Our Mail-Order Pharmacies Market Overview, 215 pgs. in length, includes the Industrys Overview and Trends, as well as profiles of nearly 40 of the leading industry participants.
This Mail-Order Pharmacies Market Overview provides the information and analysis you need to gain an understanding of the of the Mail-Order Pharmacy market and the trends which affect it. This Mail-Order Pharmacies Market Overview, 215 pages, also identifies nearly 40 of the major market participants and provides information on each company which includes: company background, company strategy, financial and statistical information (when available), products and services, and recent activities.
Topics Covered
Industry Overview
Aetna Pharmacy Management
AmeriPharm
AmerisourceBergen/PharMerica/PMSI
BeneScript Services
BioScrip
Caremark Rx
CIGNA Tel-Drug
drugstore.com
EBRx, Inc.
Envision Pharmaceutical Services
Express Scripts
4D Pharmacy Management Systems
Immediate Pharmaceutical Services
Innoviant
Kroger Managed Prescription Drug Plan
Maxor National Pharmacy Services
Medco Health Solutions
Mediplan Health
NBRx
NMHCRx
PBM Plus
Pequot Pharmaceutical Network
PharmaCare Direct
Pharmacy Services Group
Prescription Solutions
Prime Therapeutics
Rite Aid
RxAmerica
RxWest
Safeway-SMCRx
Sav-Rx Prescriptions Services
Serve You Custom Prescription Management
Walgreens Health Initiatives
Wal-Mart Pharmacy Services
Wellpartner
WellPoint Pharmacy Management
Sources
For more information visit http://www.researchandmarkets.com/reports/c30726
Confusion Surrounding The Medicare Part D Controversy is Reaching Panic Level For Seniors and Family Members AlikeThere is a lot of confusion right now concerning the Medicare Part D issue. Pressure is mounting because seniors feel they are being forced or intimidated into making a decision with Medicare Part D. The threat of penalties for not joining in time is cause for concern, and the deadline is May 15th.
(PRWEB) January 12, 2006 -- Seniors are panicky, confused and angry at the way Medicare part d is being handled. There are gapping holes in the plan when it is examined closely and most people will not be able to take advantage of the ideal savings because that ideal savings is based on a specific annual expense.
Here are some facts that may help answer the concerns and make the issue a little clearer.
The Government is enforcing Medicare Part D. Proof of this is evident if considering the penalties individuals will incur by not joining Medicare Part D by May15th. The accumulative 1% penalty (per month) can become expensive over time and looks counter productive. It seems more likely the Government agenda is geared towards herding the public into a central plan and closing the doors for international prescription imports.
Medicare Part D is great if individual retail expenses are exactly $2250 each year. The further away annual costs are from that perfect amount, the less effective the plan is.
Medicare Part D is deceptive because it is presented as a 75% savings when in reality the savings are at best 60% when the perfect amount of $2250 is spent.
Medications that are not insured obviously reduce the savings. If you spend exactly $2250 retail on insured medications then your savings will be significant, probably between 50% and 60%. So who will hit that perfect amount?
Here are some scenarios to consider: (Based on $250 deductible and monthly premiums of $35)
* Spend $1200 on insured medications - Savings will be about 16%
* Spend $3000 on insured medications - Savings will be about 36%
* Spend $4000 on insured medications - Savings will be about 27%
The Perfect Situation:
* Spend $2250 on insured medications - Savings will be 52%
Anyone who is spending more than $2250 on prescriptions each year will be unhappy paying full retail after spending beyond the $2250 mark, and possibly angry when they realize the monthly premiums are still due.
Spokesman for Professional Services Canada Darwin Corby, has this advice:
"Sit down and calculate all your prescription expenses at full retail by phoning a local Pharmacy. Get familiar with your Medicare Part D costs. Add the $250 deductible and monthly premiums together with the %25 not covered in the first $2250. Then add the full retail you will be paying in the doughnut hole on top of your costs. (The doughnut hole is the gap between $2250 and $5100)
Subtract the deductible, monthly premiums, doughnut hole expenses and 25% from the savings to find your approximate savings for the year. You also need to understand that reaching the ideal savings is highly unlikely."
A simple webpage chart is provided to help understand Medicare Part D on this page http://www.medicareaide.com/supplement.html
Recommendations:
Use a Canadian Prescription service to help avoid the Doughnut hole if expenses are high. Join a low cost Medicare Part D plan to avoid the penalties if expenses are low. Enquire about Canadian prescription prices to maximize savings
Take full advantage of Medicare Part D
Use a Canadian Pharmacy together with / or in place of Medicare part D
Call for more information
1-800-946-4820
http://www.medicareaide.com
Professional Services Canada
Contact: Dwain Berlin
1-800-946-4820
#1 Flynn Court
Port Moody B.C.
V3H4W1
www.medicareaide.com
# # #
Press Contact: Dwain Berlin
Company Name: AUTOMATIC MARKETING
Email: email protected from spam bots
Phone: 1-800-946-4820
Website: http://www.medicareaide.com
A Company That Cares - FLAVORx Develops Products to Accommodate Needs of Celiac Disease PatientsIn response to growing demand from consumers for a gluten-free and casein-free line of FLAVORx Medicinal Flavorings, President Kenny Kramm has re-vamped the products to diminish the possibilities of allergy or adverse reactions due to diet limitations. Nearly all of the 42 flavors have been modified to cater to the needs of patients who cannot consume wheat, barley, rye, oats and dairy products.
Bethesda, MD (PRWEB) January 10, 2006 -- FLAVORx, Inc., the industry standard for the flavoring of prescription and OTC drugs, now offers medicinal flavorings safe for patients suffering from Celiac Disease, gluten intolerance or wheat allergies. Additionally, FLAVORx flavorings are now also casein-free and thus friendly to consumers who face troubles digesting dairy products. In a response to consumer requests for gluten and casein-free products, the company has taken it upon itself to re-vamp its formulations to make them safe and available to consumers of all needs.
Having received calls from many parents and pharmacists regarding the gluten and casein content in FLAVORx flavorings, Kenny Kramm, President and CEO of FLAVORx, began to realize that this was a limiting factor to many children. Thus began the modification process for the existing FLAVORx product line to address the dietary limitations that consumers with Celiac Disease face. According to Kramm, Disease, allergy or intolerance shouldnt prevent a child from being able to have their medication taste palatable. The limitations that these children (also teens, adults and the elderly) have to face on a day to day basis are already more than most could endure, adding bad-tasting medicine to that list is adding insult to injury. With gluten and casein-free flavors, patients can rest-assured that they will still receive the maximum benefit from their medications, without having to worry that the addition of a flavoring could cause further complication because of a specific allergy or disease.
Working with all 42 flavors, Kramm had the formulations tested for safety and efficacy, to ensure they would still be appetizing and successful to use in medications. By making these modifications, 41 of the 42 flavors are now completely safe for consumers with a chronic reaction to gluten and/or dairy products, and also better for those consumers who may be unaware of allergic conditions. This vastly reduces any incidence of complication with allergy or adverse reaction when taking a FLAVORx medication. The one flavor that is still being modified is Strawberry Cream, which contains a very small amount of casein, a milk protein; however FLAVORx researchers are currently working to alter this component while maintaining the taste characteristics and medication covering properties.
Celiac Disease is the result of an adverse reaction to glutens that causes destruction of villi in the small intestine and results in inadequate nutrient absorption. Patients with Celiac Disease are typically unable to consume gluten products containing wheat, rye, barley and oats including common items like breads, pasta, cookies and even alcoholic beverages like beer. Celiac Disease affects 1 in 133 Americans, and there is no prescriptive cure for Celiacs, except to maintain a gluten-free diet. Doing so allows for immediate repair of villi in the small intestine, and likewise regression back to a diet containing gluten can be immediately detrimental. Therefore, even a small amount of gluten, like that in a few drops of flavoring, could cause a negative reaction. When asked why he took such great lengths to ensure that the flavorings were absolutely without gluten or casein, Kramm simply stated, When it comes to medicine, you just cant be too careful and everybodys health circumstances must be taken into consideration.
Symptoms of Celiac Disease include both intestinal and non-intestinal disorders including abdominal pain, general swelling, hair loss and malnutrition, as well as additional complications like lactose intolerance. Similarly, allergies and intolerance to gluten and casein can lead to such reactions as GI symptoms (gas, bloating) and respiratory problems.
FLAVORxs development of flavors that are gluten and casein-free exemplifies the companys dedication to consumer needs, so patients can be confident that flavoring their medications will not cause adverse reactions to their medications.
For more information, please visit www.flavorx.com or contact Teresa Chen at 800.884.5771, extension 234.
###
Press Contact: Teresa Chen
Company Name: FLAVORX, INC.
Email: email protected from spam bots
Phone: 240.223.0953
Website: www.flavorx.com
Medical Risk Management Associates, LLC (MRMA) Shares Top Honors as Technology Innovator in Patient SafetyMedical Risk Management Associates, LLC (MRMA) has been designated as a top award winner by the 2005 The Emerging Technologies and Healthcare Innovations Congress (TETHIC) for Use of Technology for the Improvement of Patient Safety. The award was given for MRMA's two software tools, Root Cause Analyst and Failure Mode Analyst, which respectively facilitate root cause analysis and failure mode & effects analysis in the healthcare environment.
Washington D.C. (PRWEB) January 11, 2006 -- The TETHIE Awards recognize healthcare industry leadership in the areas of innovation, technology, implementation, best practices, and research. In the category of technological innovation for patient safety, MRMA has been honored for its achievements in software-facilitated root cause analysis (RCA) and failure mode & effect analysis (FMEA) in the healthcare environment. MRMA's two software products guide the analysis team through the respective analytic process of RCA and FMEA, providing for direction, expert prompting, documentation, reporting and graphical presentation of the analyses. The underlying analytic logic structures have designed specifically for application to the healthcare industry.
We are both pleased and honored to have been recognized for our contribution to patient care, said Kenneth Hirsch, MD, PhD, medical director of MRMA. This underscores our firms commitment to safety of our patients and effectiveness of the organizations that provide clinical care.
About Medical Risk Management Associates, LLC (MRMA):
MRMA is a leading provider of patient safety software, training and consulting services, with specific focus upon the areas of Root Cause Analysis and Failure Mode & Effects Analysis. Its software and underlying analytic methodologies have been created by and for healthcare professionals, for exclusive application to the healthcare environment. Its software products are strongly supported by integrated traing and consultative services.
About The Emerging Technologies & Healthcare Innovations Congress (TETHIC):
Jointly developed by Health Care Conference Administrators, LLC and The Emergent Group, LLC, TETHICs purpose is to address the challenges and opportunities presented by new technology and healthcare innovation, provide a strategic setting, and present specific and practical solutions currently being implemented in the field.
To learn more about Medical Risk Management Associates, LLC and its products and services, go to www.Sentinel-Event.com.
###
Press Contact: Kenneth A Hirsch, MD, PhD
Company Name: MEDICAL RISK MANAGEMENT ASSOCIATES, LLC
Email: email protected from spam bots
Phone: 808-754-3639
Website: http://www.Sentinel-Event.com
White Paper on Electronic Medical Records Published2K Electronic Medical Records publishes white paper on the effects of implementing Electronic Medical Records in your practice.
REDONDO BEACH, Calif. (PRWEB) January 10, 2006 -- 2K Electronic Medical Records, located in Redondo Beach, California has published a white paper entitled Electronic Medical Records and Your Practice.
The white paper takes an in-depth look at electronic medical records (EMR), the effects implementation can have on your practice, questions practioners and office personnel should ask before purchasing EMR software among other things.
2K Electronic Medical Records is a leading provider of electronic medical software for physicians and medical billing services.
Tammy Harrison, President of 2K Electronic Medical Records said, Looking back at 2005 with President Bushs request to have all medical records be electronic within the next 10 years, the national disasters -- like hurricane Katrina our country has experienced, we felt examining the EMR process would help practioners and medical billing specialists make an informed decision that is right for them.
Ms. Harrison said, Many practices begin to re-evaluate their business processes when they implement EMR software. Existing office procedures, patient safety and satisfaction, as well as cost effectiveness are all important factors.
Here are some questions she advises those evaluating EMR ask before purchasing software:
1. What goals do you expect to achieve?
2. What basic features does your practice need?
3. How will you enter old data into the system?
4. What is your budget?
5. Who in the office will assist with implementation?
2K Electronic Medical Records specializes in helping medical establishments evaluate the needs of physicians and medical billing services and develop tailored medical billing software options and solutions.
You can receive a copy of the free white paper at http://www.2kmedicalrecords.com/electronic_medical_records_white_paper.html
###
Press Contact: Kelly Robbins
Company Name: KELLY ROBBINS LLC
Email: email protected from spam bots
Phone: 310-937-8924
Website: www.2kmedicalrecords.com
Effective Pain Relief Without Medications: Stanford Engineer Introduces Impressive New Acupuncture Without NeedlesGary Craig (Stanford 62) has discovered a clear link between our bodily pains and our negative emotions. Used properly, EFT (Emotional Freedom Techniques) simultaneously removes or reduces emotional and physical pains in about 80% of the cases. The basics are available free on his website.
San Francisco, CA (PRWEB) January 9, 2006 -- A growing number of physicians are tossing the meds for some of their pain-ridden clients. Because of the dangers of many medications, a new Acupuncture Without Needles procedure is being substituted, often with astonishing results.
EFT (Emotional Freedom Techniques) is a dual-purpose method introduced by Stanford Engineer Gary Craig. After thousands of clinical uses it has proven effective 80% of the time and simultaneously removes or reduces both emotional and physical pain. The process involves stimulating established acupuncture meridian points by tapping on them with the fingertips. No needles are necessary.
As Eric Robins, MD states, "Someday the medical profession will wake up and realize that unresolved emotional issues are the main cause of 85% of all illnesses. When they do, EFT will be one of their primary healing tools...as it is for me."
EFT makes clear the link between our physical pains and our negative emotions. Once anger, stress, anxiety and fear abate with EFT, the corresponding pains usually subside. Sometimes the results are astonishing. Examples: Migraine headaches vanish on the spot, never to appear again. Frozen shoulders loosen and regain normal mobility. A gout sufferer goes dancing without pain.
As EFT user Bill Edens states, We are very excited about this EFT program. My wife got rid of her back pain and too frequent headaches she has had for years. I no longer have acid reflux and no longer have to take a prescription drug for it.
Hundreds more cases fill the EFT website. The basics can be learned and applied by anyone and are available free in the downloadable 79 page EFT Manual. See http://www.emofree.com/downloadeftmanual.htm?ref=prw . The finer points of EFT are available on low cost DVD sets and purchasers are encouraged to make up to 100 copies to give (not sell) to others.
For additional information, or for a complete press kit, contact:
Gary Craig
Emotional Freedom Techniques
707-785-2848
http://www.emofree.com
# # #
Press Contact: Gary Craig
Company Name: EFT
Email: email protected from spam bots
Phone: 707-785-2848
Website: http://www.emofree.com
Arcadian Health Plan Selects Dynamic Healthcare Systems to Meet Medicare ChallengesDynamic Healthcare Systems, a provider of innovative solutions for Medicare-focused health plans, today announced that Arcadian Health Plan, Inc., a provider of Medicare Advantage health plans, purchased two major components of Dynamics Voyager Medicare Suite.
IRVINE, CA (PRWEB) January 9, 2006 -- Dynamic Healthcare Systems, a provider of innovative solutions for Medicare-focused health plans, today announced that Arcadian Health Plan, Inc., a provider of Medicare Advantage health plans, purchased two major components of Dynamics Voyager Medicare Suite.
Part of Dynamics powerful Voyager software suite, the two modules RAPS Management and HCC Analytics will provide Arcadian with a critical advantage toward meeting current challenges in managing explosive Medicare populations, helping the company maximize revenues and profitability by streamlining the critical risk adjustment phase of the reimbursement process.
After an in-depth review of several systems, says David Lontok, President of Arcadians Management Services Organization, Dynamic was selected for its flexibility in managing our data, in-depth analytics, reporting capabilities, HIPAA compliance and intuitive nature of its interface. Additionally, Dynamic fields an experienced team with a deep understanding of crucial technologies, and how to solve problems in the Medicare space. Were very optimistic about 2006.
The RAPS Management module should fulfill that role amply by helping Arcadian automate the way they accept, manage and exchange RAPS encounter data in conjunction with The Centers for Medicare & Medicaid Services, or CMS. The HCC Analytics solution analyses and enriches that information by applying complex algorithms to identify suspected missing or mis-coded diagnostic ICD9 codes and using secondary data like prescriptions, lab results and authorizations.
We are very pleased that Arcadian Health Plan selected Dynamic to address their challenges of managing and analyzing risk adjusted data and reimbursements. With CMS implementing the risk adjustment payment model at 100% in 2007, plans, MSOs and providers must really focus on the way they handle encounter data today, says Ken Stockman, Dynamics founder and CEO. Their success directly depends on the quality of that information, with complete, accurate coding and reporting being key to full reimbursement. Our Voyager solution was specifically designed to help plans and MSOs address these challenges.
About Arcadian Health Plan, Inc.
Arcadian Health Plan (AHP) is a Centers for Medicare & Medicaid Services-licensed Medicare Advantage health plan. Through state or locally-branded health plans, AHP is focused on offering value-oriented Medicare health plan options to Medicare beneficiaries who reside in small to medium-sized communities that currently do not have affordable Medicare replacement plan options available.
About Dynamic Healthcare Systems
Dynamic Healthcare Systems, Inc. was founded on delivering comprehensive solutions for Medicare Advantage health plans and MSOs striving to succeed amid new and evolving regulatory requirements. Headquartered in Irvine, California, the company brings world-class innovations to middle market companies serving the Medicare population. Dynamic Healthcare Systems can be reached at (949) 975-877. www.dynamichealthsys.com.
###
Press Contact: Jay Baker
Company Name: DYNAMIC HEALTHCARE SYSTEMS INC.
Email: email protected from spam bots
Phone: 949-975-1877
Website:
================================================================
Drug Discovery Online Newsletter - http://www.drugdiscoveryonline.com
Friday, January 06, 2006
================================================================
-------------------------------------
TOP NEWS STORIES
-------------------------------------
1) TransTech Pharma and Boehringer Ingelheim Initiate $54 Million Drug Discovery Collaboration
2) Perlegen Forms Collaboration With Genentech in Cancer Genetics
3) Pfizer Invests $50 Million In Perlegen Sciences
4) Quintiles Book Shows Path To High-Performance Phase IIIB-IV Research
5) Xenogen Announces Extension of Global Licensing Agreement
6) Vaccine For Chronic Myeloid Leukemia Active In Patients With Persistent Disease
7) The Personalized Medicine Market Aims to Match the Most Appropriate Drug to the Right Person
8) Cetek Raises $10 Million To Advance Drug Discovery And Development
---------------------------------------
1) TransTech Pharma and Boehringer Ingelheim Initiate $54 Million Drug Discovery Collaboration
TransTech Pharma, Inc. recently announced a worldwide research and license collaboration with Boehringer Ingelheim GmbH using TransTech's proprietary TTP Translational Technology(R)...
http://www.drugdiscoveryonline.com/
2) Perlegen Forms Collaboration With Genentech in Cancer Genetics
Perlegen Sciences, Inc. announced today that it has begun a collaboration with Genentech, Inc. to study the genetics of cancer...
http://www.drugdiscoveryonline.com/
3) Pfizer Invests $50 Million In Perlegen Sciences
Perlegen Sciences, Inc. announced recently that Pfizer Inc has made a $50 million equity investment in Perlegen, taking a twelve percent position in the private biotechnology company...
http://www.drugdiscoveryonline.com/
4) Quintiles Book Shows Path To High-Performance Phase IIIB-IV Research
Patients, physicians, payers and politicians are calling for more information on the risks and benefits of prescription drugs. At the same time, some organizations are questioning the value of direct-to-consumer advertising...
http://www.drugdiscoveryonline.com/
5) Xenogen Announces Extension of Global Licensing Agreement
Xenogen Corporation announced recently an extension of its licensing agreement with Novartis for up to two more years...
http://www.drugdiscoveryonline.com/
6) Vaccine For Chronic Myeloid Leukemia Active In Patients With Persistent Disease
Breakthrough Therapeutics, a privately owned biotechnology company, recently announced the presentation of positive interim data for a novel vaccine known as VAX100 for patients with persistent chronic myeloid leukemia (CML) while on imatinib mesylate (Gleevec(R); Novartis)...
http://www.drugdiscoveryonline.com/
7) The Personalized Medicine Market Aims to Match the Most Appropriate Drug to the Right Person
The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype...
http://www.drugdiscoveryonline.com/
8) Cetek Raises $10 Million To Advance Drug Discovery And Development
Cetek Corporation announced it has raised $10 million to advance its proprietary drug discovery platform and its emerging pipeline of compounds to treat cancer and infectious diseases...
http://www.drugdiscoveryonline.com/
-------------------------------------
FEATURED PRODUCTS
-------------------------------------
1) Analytical SFC with fractionation
2) Chromatography
3) LyoStar IIT Research and Development Tray Dryer
4) Nano Flow Sensor
5) Vetter Development Service
---------------------------------------
1) Analytical SFC with fractionation
Thar's analytical SFC offers faster separations (4 times faster than HPLC) due to the low viscosity of the primary mobile phase (CO2). Additionally, the analytical SFC utilizes Thar's new high pressure fluid pumping module that archieves flow rates of 0.1 g/min to 10 g/min at pressures up to 400 bar...
http://www.drugdiscoveryonline.com/
2) Chromatography
Disposable Membrane Chromatography units are designed for the rapid selection of appropriate chemistry and method development. The Mustang membrane chromatography starter kit includes both strong anion and cation exchange membrane chromatography Acrodisc® units, as well as specific endotoxin removal Acrodisc units...
http://www.drugdiscoveryonline.com/
3) LyoStar II(TM) Research and Development Tray Dryer
LyoStar II(TM) Research and Development Tray Dryer for process development for scale-up, Product processing for stability studies, Formulation work...
http://www.drugdiscoveryonline.com/
4) Nano Flow Sensor
Developed by Upchurch Scientific® in cooperation with Honeywell, this noninvasive Nano Flow Sensor reports flow rate in the nanoliter through low microliter-per-minute range...
http://www.drugdiscoveryonline.com/
5) Vetter Development Service
As specialists in the handling of highly sensitive active substances, we can guarantee that your liquid or freezedried active substances will be produced quickly, efficiently and carefully...
http://www.drugdiscoveryonline.com/
-------------------------------------
FEATURED DOWNLOAD
-------------------------------------
Datasheet: Pallsep(TM) Vibrating Membrane Filtration Technology
In the Pallsep system, controlled horizontal oscillation moves the membrane
elements through the feed fluid over 50 times per second...
http://www.drugdiscoveryonline.com/
-------------------------------------
CONSULTING SERVICES
-------------------------------------
ProSavvy brings clients with projects together with consultants who have the right expertise. We also provide consultants the ability to access project opportunities. Visit http://www.drugdiscoveryonline.com/ and post your project today!
-------------------------------------
TRAINING RESOURCES
-------------------------------------
Thinking About Continuing Your Education?
Let us help you find the right school for you. Whether you would like to get an Associate's Degree, Bachelor's Degree or Master's Degree we can help you pinpoint which schools to choose from.
http://www.drugdiscoveryonline.com/
-------------------------------------
TRADE PUBLICATIONS
-------------------------------------
Browse from the extensive list of complimentary trade publications. Visit http://www.drugdiscoveryonline.com/ for more information.
-------------------------------------
NEWSLETTER SUBSCRIPTION
-------------------------------------
If you do not currently receive the Drug Discovery Online newsletter and wish to become a subscriber, click here:
http://www.drugdiscoveryonline.com/
-------------------------------------
ADVERTISE ONLINE
-------------------------------------
If you are interested in advertising with Drug Discovery Online, and would like more information, click here:
http://www.drugdiscoveryonline.com/
==========================================================
(c)Copyright 2005 VertMarkets LLC, 5 Walnut Grove Drive, Suite 320, Horsham, PA 19044-2245. All rights reserved.
California Governor Urges Drug Imports; Canadian Pharmacies Have Already DeliveredGovernors endorsement verifies that drug importation from Canada is inherently safe and cost effective. Licensed Canadian pharmacies have already demonstrated an impeccable track record by delivering affordable drugs to millions of Americans.
Calgary, AB (PRWEB) January 5, 2005 -- This week California Governor Arnold Schwarzenegger appealed to Congress to allow Americans to import affordable prescription drugs from Canada and other countries. In a letter to Congressional leaders he acknowledged that drug prices continue to escalate and his own effort to lower the cost of prescription drugs has been insufficient. Whether a sincere gesture or election year posturing, the notion of acquiring safe and affordable medications is already available to Californians and to all Americans. Licensed online Canadian pharmacies like Minit Drugs (www.Pharmacy-Online.ca) have been safely dispensing prescriptions to Americans for years.
The political and legal debate will rage on but at the end of the day, any American, regardless of age, income or social status can order their medications by mail from a reputable online pharmacy in Canada and they will get the real McCoy, says Barney Britton, President of Minit Drugs (www.Pharmacy-Online.ca). Scare tactics abound but the fact is that we dispense approved drugs from regulated pharmacies. The pill is the same, the only difference is the price and the label.
Gestures by Governor Schwarzenegger and others only confirm that drug importation from Canada is a feasible option for Americans regardless of legislative status. The key is simply to select legitimate online Canadian pharmacies.
Methods to verify the legitimacy of an online Canadian pharmacy include:
1. Check for a provincial pharmacy license number
2. Verify the pharmacy has a physical address in Canada
3. Look for toll free phone and fax numbers
4. Verify that a prescription and patient medical questionnaire is required
5. Look for a CIPA certification seal
Another attribute that truly distinguishes a pharmacy from all others is IMPAC accreditation (www.impacsurvey.org). Minit Drugs is one of only six Canadian pharmacies to achieve the IMPAC accreditation.
As many as ten state governments have inspected and endorsed Canadian pharmacies to dispense their drugs to American patients. In every case politics and corporate financial interests threatened to de-rail the initiative. But regardless of the obstacles, Canadian pharmacies continue to offer significant savings to Americans without compromising safety.
Debating legislation is one thing but actually helping people to afford their medications is another. We do it everyday and the only permission we ask for is the patients.
Minit Drugs is a licensed pharmacy located in Calgary, Alberta (AB License # 1657) and is CIPA certified and IMPAC accredited. All Canadian drugs are approved by Health Canada and dispensed by licensed pharmacists.
Contact:
Barney Britton
President, Minit Drugs
Ph. 1-877-530-3743
website: www.Pharmacy-Online.ca
# # #
Press Contact: Barney Britton
Company Name: Minit Drugs
Email: email protected from spam bots
Phone: 1-877-530-3743
Website: www.Pharmacy-Online.ca
Building Interoperability into Medical InformationModern health information systems today are proprietary and often only serve one department making it impossible to easily share data across one facility, never mind across different facilities or countries. A big problem, it makes it difficult for doctors to capture a complete clinical history of a patient. But one project hopes to overcome this.
(PRWEB) January 5, 2006 -- Modern health information systems today are proprietary and often only serve one department making it impossible to easily share data across one facility, never mind across different facilities or countries. A big problem, it makes it difficult for doctors to capture a complete clinical history of a patient. But one project hopes to overcome this.
The healthcare interoperability problem can be investigated in two categories: Interoperability of the healthcare messages exchanged and interoperability of electronic healthcare records [EHRs, says Professor Asuman Dogac, Director of the Software Research & Development Center in Turkey, and ARTEMIS project coordinator.
Right now messaging interfaces, or interface engines, are used to exchange information among different healthcare information systems. Currently, the Health Level 7 (HL7) Version 2 Messaging Standard is the most widely implemented.
Unfortunately, HL7 V2 compliance does not imply direct interoperability between healthcare systems, because V2 has no explicit information model. Instead it has rather vague definitions for many data fields and contains many optional fields.
EHRs suffer from similar problems. An EHR is digitally stored healthcare information about an individual that supports continuity of care, education and research, while ensuring confidentiality. A number of standardisation efforts are progressing to provide EHRs interoperability. However, an exchange of well-structured and machine-processable EHRs has not been achieved yet in practice.
ARTEMIS provides the desperately required interoperability between medical information systems through semantically-enriched Web services that use defined meanings of individual pieces of parameters. ARTEMIS uses existing standards, such as HL7, as a basis for defining both the service action semantics and the message semantics.
For EHRs, ARTEMIS uses constraint rules for specific clinical concepts, called archetypes, rather than distinct entities in the reference information model. It annotates their archetypes with ontologies, an established list of definitions, and then composes templates from archetypes and retrieves corresponding data from the underlying medical information systems.
To complicate matters, in most countries there are no unique person identifiers that would be valid for the whole lifetime of an individual and used by all parties in healthcare and for all episodes of care. In many cases several identifiers for a patient exist even within a single organisation.
Consequently a protocol is needed that allows the identification of patients by means of non-unique patient-related attributes. ARTEMIS developed a Patient Identification Process (PIP) Protocol. PIP provides a solution for continuity of care by locating and accessing prior clinical records and provides comprehensive security and privacy protection mechanisms.
Currently, the industrys Integrating the Healthcare Enterprise (IHE) initiative proposes the Retrieve Information for Display (RID) integration profile to allow users retrieve and display patient-related documents on systems other than the document keeping systems. Although it is well suited for use in a single hospital or within a trust of hospitals that belong to a single Patient Identifier Domain, it is not designed for cross-boundary access on information stored in different hospitals.
ARTEMIS middleware infrastructure extends the IHE RID protocol for cross-enterprise search and access to patient-related clinical information, even if no Master Patient Index is available, and without modifications to existing information source actors. Applied to the ARTEMIS infrastructure, the RID Information Source and Display actors may be located in different institutions using different Patient ID domains and different sets of demographic data.
At the Healthcare Information and Management Systems Society annual conference in San Diego, February 2006, "we will run a demonstrator that will realise a scenario where, after an accident, a patient is admitted to the most appropriate hospital from the ambulance, says Dr Dogac. The patient will be admitted before the ambulance arrives at the hospital, via a mobile device. The hospital admissions service will then automatically seek out any relevant healthcare records of the patient in the ARTEMIS P2P network, and presents them to the doctor, although the hospitals discovered may not be using interoperable standards with each other. This is a considerable improvement over current systems."
Dr Dogac will begin a new project, SAPHIRE, in the next months. "That project will seek to extend the functionality of ARTEMIS. It will expose medical sensor data as semantically-enriched Web services. It will process sensor output, the patient's medical history and clinical guidelines to help physicians with diagnoses and treatment."
But even without these new services, ARTEMIS already represents a major advance; it enables clinicians to capture the complete clinical history of a patient that may be spread out over a number of different institutes that do not interoperate.
###
Press Contact: Tara Morris
Company Name: IST RESULTS
Email: email protected from spam bots
Phone: +90-312-2105598 21
Website: http://istresults.cordis.lu/index.cfm/section/news/tpl/article/BrowsingType/Features/ID/79928
I had my Chitika account suspended the other day (December 29, 2005) and they will not respond to the calls, emails, and support ticket I entered on their site.
I wanted to know what the problem was and try to resolve it, but they won't get in touch with me no matter what I do. So I am starting the big job of pulling all of their ads from the sites I added them to. Man, what a pain!
My sites weren't making much from them anyway, I think they owe me $30-$40, but I had been working to try and generate more traffic to the sites that have their ads. Now they pull this BS.
So if you were considering using Chitika on your site(s), I would recommend instead that you copy the style of ads they were using and try that with some good affiliate programs. The ad style seemed to be effective, but the company really, really sucks.
I thought I waited long enough to make sure it was going to be worth the trouble, but at least now some of you won't have to go through what I am. The program from Google is so far the easiest, the best run, and pays very well so I can recommend that you try that completely.
Sigma-Tau Pharmaceuticals, Inc. Launches New Corporate Web SiteSigma-Tau Pharmaceuticals, Inc. is dedicated to providing new therapies and new hope for patients with rare diseases. There are some 6,000 identified rare diseases that affect approximately 10 million patients in the United States. The founding principle and core belief of Sigma-Tau Pharmaceuticals, Inc., a wholly owned subsidiary of Sigma-Tau S.p.A., is that finding therapies for rare diseases is just as important as finding ones for more common diseases. After all, to the patient, theres nothing rare about their condition.
Gaithersburg, MD (PRWEB) January 3, 2006 -- Sigma-Tau Pharmaceuticals, Inc. announced today that the company has launched its new corporate web site at www.sigmatau.com.
Sigma-Tau Pharmaceuticals, Inc. is dedicated to providing new therapies and new hope for patients with rare diseases. There are some 6,000 identified rare diseases that affect approximately 10 million patients in the United States. The founding principle and core belief of Sigma-Tau Pharmaceuticals, Inc., a wholly owned subsidiary of Sigma-Tau S.p.A., is that finding therapies for rare diseases is just as important as finding ones for more common diseases. After all, to the patient, theres nothing rare about their condition.
To that end, Sigma-Tau Pharmaceuticals has been focused on rare diseases since its founding, and was one of the first companies to obtain an Orphan Drug Designation in the United States more than 20 years ago.
Our core belief is that no patient should go untreated simply because the disease they are fighting is so rare that only a few thousand, or even a few hundred, suffer from the condition. Every one of us shares an unwavering commitment to develop novel products and therapies for patients with rare diseases. This unique vision, indeed, our passion, is woven into everything we do.
>From our people, to our pipeline, to our partners, and most importantly, to our patients, Sigma-Tau Pharmaceuticals is dedicated to the relentless pursuit of creating treatments for rare diseases.
Sigma-Tau Pharmaceuticals, Inc., a wholly owned U.S. subsidiary of Sigma-Tau S.p.A., is particularly proud of its research in the area of rare diseases. For additional information about the company, please visit http://www.sigmatau.com. If you need to contact us for further information, please call 1-800-447-0169 and ask for the Marketing Group.
# # #
Press Contact: Yamil Hernandez
Company Name: Sigma-Tau Pharmaceuticals, Inc.
Email: email protected from spam bots
Phone: 1-800-447-0169
Website: www.sigmatau.com